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Abstract
Lasso peptides, such as microcin J25, BI-32169, lariatin and capistruin, are a structurally unique
and pharmacologically relevant class of RiPPs (ribosomally synthesized and posttranslationally
modified peptides) natural products. Compared with other intensively modified RiPPs, such as
lantibiotics, lasso peptides only have a unique knotted topology in which the tail of the peptide is
threaded through an N-terminal macrolactam ring and trapped by steric hindrance of bulky side
chains stabilizing the entropically disfavored lasso structure. Except for this unusual knot
structure, further posttranslational modifications on lasso peptides are very rare. Besides, lasso
peptides have so far only been isolated from Proteo- and Actinobacterial sources. In this thesis,
the lasso gene cluster from the Firmicute P. dendritiformis was investigated. Paeninodin, a new
lasso peptide with an unusual phosphorylation at the side chain of the last serine was
discovered by expression of this cluster in a heterologous host. The Paeninodin lasso peptide
was isolated from a culture pellet. Mass spectrometric, carboxypeptidase Y assays and IM-MS
studies proved paeninodin to be a new representative of lasso peptides. Morever, the
biosynthetic pathway of modified lasso peptide was delineated through in vivo and in vitro
studies. The kinase turned out to be a novel lasso peptide precursor kinase with wide substrate
specificity. These results provide a way for the generation of novel lasso peptide analogs and,
thereby, would facilitate lasso peptide engineering in the future.
ABSTRACT
XII
Zusammenfassung
Lassopeptide, wie Microcin J25, BI-32169, Lariatin und Capistruin, sind eine strukturell
einzigartige und pharmakologisch relevante Gruppe von RiPP-Naturstoffen (ribosomal-
synthetisierte und post-translational modifizierte Peptide). Verglichen mit anderen stark
modifizierten RiPPs, wie Lantibiotika, haben Lassopeptide nur eine einzige verknotete
Topologie, in der der Schwanz des Peptids durch einen N-terminalen Makrolactamring gefädelt
ist und dort durch sterische Wechselwirkungen von sperrigen Seitenketten festgehalten wird,
wodurch die entropisch ungünstige Lassofaltung stabilisiert wird. Mit Ausnahme dieser
ungewöhnlichen Knotenstruktur sind weitere post-translationale Modifikationen an
Lassopeptiden sehr selten. Des Weiteren wurden Lassopeptide bisher nur aus proteo- und
actinobakteriellen Quellen isoliert. In dieser Doktorarbeit wurde der Gencluster aus dem
Firmicutes P. dendritiformis untersucht. Es wird die Entdeckung von Paeninodin, einem neuen
Lassopeptid mit ungewöhnlicher Phosphorylierung an der Seitenkette des letzten Serins, durch
Expression des zugehörigen Genclusters in einem heterologen Wirt beschrieben. Paeninodin
konnte aus den Zellen der Expressionskultur isoliert werden. Massenspektrometrische und
Carboxypeptidase Y Assays sowie IM-MS Studien bewiesen, dass Paeninodin ein neuer
Vertreter der Lassopeptide ist. Zusätzlich wurde die Biosynthese von modifizierten
Lassopeptiden beschrieben auf Basis von in vivo und in vitro Studien. Es zeigte sich, dass die
Kinase eine neuartige Lassopeptid-Vorläufer-Kinase mit breiter Substratspezifität ist. Diese
Ergebnisse ermöglichen eine neue Route zur Generierung von neuartigen Lassopeptidanalogas
und fördern das Engineering von Lassopeptiden in der Zukunft.
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1. Introduction
1.1 Natural Products
Natural products, as the name implies, are chemical compounds of natural origin1, 2. They are
generally biologically functional compounds isolated from all kinds of natural sources, such as
plants, microorganisms, fungi and animals3. Due to the diverse pharmacological or biological
activity, natural products have played significant roles in science and medicine4. Humanity has
already learned to prepare “mixer crude extract” to protect themselves against some diseases
since ancient times. Quinine, for example, is such a medicine that has been used to prevent
and treat malaria and to treat babesiosis for a long time5. With the great development of
biological and chemical research in the 19th century, the start of the wide use of natural
products marked the birth of modern medicine6. It has been suggested that more than 60 % of
drugs used in clinical applications are derived from natural products or synthetic analogs1. The
acetylsalicylic acid (aspirin, prepared in 1897) is an example of one of the first semisynthetic
drugs based on a natural product which is still widely used today7. Another milestone for
modern medicine was the discovery of penicillin as the first antibiotic in 19298. Its large-scale
fermentative production in the 1940s was one of the most important steps in modern medicine’s
use of natural products of microbial origin8. Later on, more and more natural products or
derivatives from them were approved for clinical applications2, 6. Even today, natural products
are still the main source or are used as starting points for drug discovery. The Nobel Prize in
Physiology or Medicine, for example, was awarded to natural products again last year.
Avermectin discovered by William C. Campbell and Satoshi Ōmura and Artemisinin discovered
by Youyou Tu have revolutionized the treatment of the most devastating parasitic diseases9.
Notably, microbial natural products are the origin of most of the drugs on the market today10.
This is due to the huge number of microbial species and their short generation times, which
endows the natural products with a rich variety of evolution11. However, it is believed that more
than 99 % of the microbial species extant have not yet been discovered. The so-called
“secondary metabolites” produced by microorganisms have a broad range of functions12. These
include pheromones that act as social signaling molecules, agents that solubilize and transport
nutrients (e.g. siderophores), and antibiotics that are used against competitors13. In fact, most
antibiotics are produced by microorganisms. Microorganisms are in constant competition for
resources and ecological niches, therefore, they need to develop all kinds of defense
mechanisms14. Meanwhile, microorganisms are also developing all kinds of protection
mechanisms in order to survive14, 15. However, these protection strategies also represent a
major problem for modern medicine which is termed “antibiotic resistant”16. Streptococcus
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pyogenes, for example, and staphylococci organisms that cause respiratory and cutaneous
infections are now resistant to all of the older antibiotics16. Therefore, searching for new
antibiotic agents and, thus, the isolation and identification of new natural substances are still
necessary.
Natural products can generally be classified into alkaloids, terpenes, polyketides, carbohydrates,
lipids and peptides, based on their chemical aspects1. Their high structural complexity is derived
from the intensively evolutionary development of their biosynthesis machinery. It, therefore,
requires broad basic research to isolate new natural substances, and characterize and
understand their biosynthetic mechanisms. We are particularly interested in natural products
from peptides. Therefore, several classes of peptide natural products, especially ribosomally
synthesized and posttranslationally modified peptides (RiPPs), and their biosynthesis routes are
described below.
1.1.1 Nonribosomal Peptides
Nonribosomal peptides, as the name implies, are synthesized in an mRNA-independent way17-19.
They are a very diverse family of natural productsof extraordinary pharmacological importance.
They are often toxins, siderophores or pigments produced by microorganisms and can be used
as antibiotics, cytostatics and immunosuppressants in commercial ways20, 21. Figure 1.1 shows
examples of the structural diversity of the bioactive compounds of nonribosomal origin22-24.
Figure 1.1:Examples of the structural diversity of bioactive compounds of NRPs.
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The assembling of these compounds is achieved by large multimodular enzymes called
nonribosomal peptide synthetases (NRPSs)20. Each module contains at least three domains:
the adenylation domain (A domain), the condensation domain (C-domain) and the peptidyl
carrier protein (PCP domain) 25, and is responsible for the incorporation of an amino acid
building block in the final product. The function of the A domain is the recognition and activation
of the respective amino acid as the aminoacyl-adenylate under ATP hydrolysis25. The activated
amino acid is then transferred to the thiol group of the phosphopantetheinyl bound in the PCP
domain and forms the peptide bond in the C domain.Upon the amide bond formation, the
elongated peptide is then transferred into the next downstream PCP domain and serves as a
donor substrate in the following condensation step25. In addition to these three essential
domains, there is also a fourth essential domain called the thioesterase (TE) domain. It is
usually located in the termination module of the assembly line. The TE domain is responsible for
the release of the product from the NRPS machinery by cyclization26.
Besides these four domains required in a NRPS assembling machine, other optional domains
can also be found, such as the epimerization (E) domain, the cyclization (Cy) domain, the
methylation (MT) domain and the formylation (F) domain27. These domains can catalyze diverse
in cis modification reactions, thus, can increase the diversity of the NRPS natural products.
What is more, in addition to all the domains mentioned above, there are also a lot of tailoring
enzymes which can be found in the NRPS gene cluster, such as methytransferase and
monooxygenases. These enzymes can catalyze diverse transmodification reactions which can
further increase the chemical diversity of the NRPS natural products27.
Figure 1.2: The structure and biosynthetic gene cluster of teixobactin. (a) The NRPS gene cluster contains two
genes – txo1 and txo2. The T domain here is equal to the PCP domain. (b) Schematicstructure of teixobactin. The N-
methylation ofthe first phenylalanine is catalyzed by themethyltransferase (MT) domain in module 1. The ring closure
between the last isoleucine and threonine (Thr) is catalyzed by the TE domain. (c) Structure of teixobactin (Figure
from ref. 29).
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Figure 1.2 shows one example of the biosynthesis of the NRPS natural product teixobactin28, 29,
a new antibiotic which was recently isolated from the uncultured bacteria Eleftheria terrae.
Teixobactin was synthesized by a two-mega enzyme complex consisting of 11 modules. Eleven
amino acids from each module were incorporated into the final antibiotic28.
1.1.2 Cyclodipeptides
Cyclodipeptides and their derivatives, called the diketopiperazines (DKPs), constitute a large
class of secondary metabolites synthesized predominantly by microorganisms30-33. Similar to
other natural products, DKPs are also a very diverse family of natural products with important
biological activities, such as antitumor, antifungal, immunosuppressive and antibacterial
activities30-32. Figure 1.3 shows examples of the structural diversity of bioactive DKPs.
Figure 1.3:Examples of the structural diversity of DKPs.
The biosynthesis of the cyclodipeptides was previously thought to be mainly synthesized by
NRPS30. However, an NRPS-independent biosynthetic pathway was discovered in 200234. It
turns out that AlbC, a novel cyclodipeptide synthease (CDPS), was involved in the biosynthesis
of albonourisin from Streptomyces noursei34.
Cyclodippetide syntheases are very small enzymes (≈ 300 aa) compared with NRPS, and are
able to form two successive peptide bonds by using aminoacyl-tRNA as a substrate. The 2,5-
DKP moiety can be synthesized after the free tRNA has been released, as is shown in Figure
1.4.
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Figure 1.4:Biosynthesis of DKPs by CDPs. The CDPs hijack the aa-tRNA to produce the 2,5-DKP moiety (Figure
from ref. 30).
The DKPs synthesized by CDPs can be modified further by tailoring enzymes30, 35-37. Similar to
other natural products, the CDPS genes in prokaryotes are generally organized into operon-like
structures. These enzymes are probably involved in modifying the cyclodipeptide. There are
couples of tailoring enzymes that have been experimentally characterized and shown to have
different activities, namely -dehydrogenation, DKP ring oxidation, methylation and C–C aryl
coupling30, 37.
1.1.3 Ribosomally synthesized and posttranslationally modified peptides
Another major class of peptide natural products is RiPPs38. These molecules have diverse
structures not directly accessible to natural ribosomal peptides39, 40. It was believed in the past
that these compounds were mainly synthesized by NRPS. However, the genome sequencing
efforts of past decades have revealed that they are RiPPs40. With the known biosynthetic gene
cluster for these compounds and genome mining methods, it was shown that these molecules
could be produced in all kinds of life, and their biosynthetic genes clusters exist widely in the
genomes sequenced currently41-43. The extensive modification endows these peptides with
unique structures that can increase their chemical stability, make them better for target
recognition and, thus, have diverse bioactivity40.
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Figure 1.5: General biosynthetic pathway for RiPPs.
The RiPPs are initially synthesized as a precursor peptide, typically 20–110 residues in length,
which is a structure gene located in the gene cluster40, 41. As shown in Figure 1.5, a typical
precursor peptide contains several segments, such as a signal peptide, leader peptide and core
peptide.A signal sequence linked to the N-terminal of the leader peptide is used to direct the
peptide to the specific cellular compartments where the posttranslational modifications will take
place. The leader peptide, which is biologically inactive, is usually important for recognition by
many of the posttranslational modification enzymes and for export44. It is usually appended to
the N-terminus of the core peptide. However, in some cases, it can also be found at the C-
terminus of the core peptide, such as bottromycins45-47. A cleavage sequence can be found
between the leader peptide and the core peptide, which is used for cleavage by some protease
or ABC transporters.The core peptide is the segment of the precursor peptide that will be
transformed into the final natural product40.
After the precursor peptide was generated, extensive posttranslational modifications (PTM)
were performed by the tailoring enzymes in the gene cluster40. After all the PTMs were
incorporated into the core sequence, the leader peptide and signaling peptide were then
proteolytically cleaved. Some PTMs also take place only after the proteolytic cleavage of the
precursor peptide40. These are mainly modifications that require the released N-terminus, such
as cyclizations. Even though the precursor peptide is of ribosomal origin, the posttranslational
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modification could significantly enhance the structural diversity of the mature products.This
allows the natural products better target recognition or an increase in the chemical, proteolytic
and metabolic stability48.
1.2 Important Classes of Ribosomally Synthesized Peptides
Some important classes of ribosomally synthesized peptides, which play an important role in the
pharmaceutical industry, are presented below.
1.2.1 Lanthipeptides
Lanthipeptides (peptides containing Lanthionine) are a family of RiPPs containing (methyl)
lanthionine residues49-51. The first lanthipeptide, nisin, was discovered in 1927 and has become
the best understood lanthipeptide. It is widely used as a food preservative in processed cheese,
meats and beverages51.
Lanthipeptides are normally small peptides that undergo extensive posttranslational
modifications. The common posttranslational modifications involve the dehydration of Ser and
Threonine (Thr) residues in the precursor peptide to yield 2,3-didehydroalanine (Dha) and (Z)-
2,3-didehydrobutyrine (Dhb), respectively52. The stereospecific intramolecular addition of a Cys
residue onto Dha or Dhb is then introduced to form a lanthionine (Lan) or methylanthionine
(MeLan) bridge (Figure 1.6)49-52.
INTRODUCTION
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Figure 1.6:Biosynthesis of nisin lantibiotic. (a) Installation of lanthionine (Lan) or methyllanthionine (MeLan) residues
into prepeptide. (b) The posttranslational maturation process of nisin (Figure from ref. 49).
Lanthipeptides can be generally classified into four classes based on the biosynthetic enzymes
that install the Lan and MeLan motif40, 49-52. Class I lanthipeptides are synthesized by two
different enzymes: a dehydratase LanB and a cyclase LanC, as shown in Figure 1.7. Class II
lanthipeptides are synthesized by a single lanthipeptide, synthetase-LanM. LanM contains two
distinguished domains: an N-terminal dehydratase domain that bears no homology to LanB, and
a C-terminal LanC-like cyclase domain. Class III lanthipeptides are also synthesized by a single
lanthipeptide synthetase, LanKC. LanKC contains three different domains: an N-terminal lyase
domain, a central kinase domain and a C-terminal cyclase domain. Class IV lanthippetides are
synthesized in a similar synthetase with three domains. The only difference is that the C-
terminal is a LanC-like Cyclase domain40, 48-52.
Figure 1.7: Overview of Lanthipeptide classification.
Lanthipeptides have showed diverse functions. Most of them are antimicrobial compounds such
as Nisin, which has been used in the food industry for more than 40 years to combat food-borne
pathogens53-55. Another example is duramycin, which is being evaluated for treatment of cystic
fibrosis56-59. In addition to the antimicrobal activity, Lanthipeptides can also show other functions.
Two recently new isolated lanthipeptides called pinensin A and pinensin B, for example, were
found to be highly active against many filamentous fungi and yeasts, but show only weak
antibacterial activity60. Another example of lanthipeptides that show very interesting bioactivity
are the morphogenetic peptides SapB and SapT from streptomycetes. These peptides are
believed to function as biosurfactants during the formation of aerial hyphae49, 61, 62.
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1.2.2 Bottromycins
Bottromycins are a family of RiPPs with intensive modifications63-65.The structure of bottromycin
contains an unusual macrocyclic amidine and a thiazole ring. In addition, four β-methylated
amino acids could be found (Figure 1.8). Bottromycin was first discovered in 1957 as an
antibiotic isolated from Streptomyces bottropensis63-65. It has been shown to inhibit methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) among
other Gram-positive bacteria and mycoplasma63-65.
Figure 1.8:Structure of Bottromycin A2.
The biosynthesis of bottromycin was studied independently by three groups in 2012. It was
shown that bottromycin was synthesized as a RiPP45-47.
Figure 1.9: Bottromycin gene cluster in S. bottropensis. The gene encoding the bottromycin precursor peptide is
shown in red.
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The gene cluster from Streptomyces bottropensis is shown in Figure 1.9. The gene cluster
contains 13 open reading frames (ORFs). The predicted function of each gene is summarized in
Figure 1.9. The precursor peptide, termed BmbC, has 44 amino acids. The amino acids forming
the bottromycin core peptide are marked in red in Figure 1.9. The sequence is Gly-Pro-Val-Val-
Val-Phe-Asp-Cys. Unlike other RiPPs, bottromycin has no leader peptide except a Met at the N-
terminal. Instead, it has a 35 residues following peptide function as a recognition peptide for
posttranslational modification45-47.
Figure 1.10: Potential biosynthetic pathway to bottromycin A2 (Figure modified based on ref 45-47).
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A biosynthetic pathway for bottromycin has been proposed by a gene-inactive experiment in
vivo (Figure 1.10). Three radical S-adenosyl methionine (SAM) methyltransferases are believed
to form β-methylate amino acid residues45-47. While the O-methyltransferase is responsible for
the formation of anester, the aminopeptidases are predicted to cleave the N-terminal methionine
residue. There are two YcaO-like proteins and it is hypothesized that one catalyzes macrocyclic
amidine formation, while the other catalyzes thiazoline formation. There are two hydrolases
which may catalyze follower peptide hydrolysis. However, the order of the posttranslational
modifications is currently not known and, hence, the order depicted in Figure 1.10 is arbitrary45-
47.
1.2.3 Thiopeptides
Thiopeptides are a growing class of sulfur-rich, highly modified heterocyclic peptide antibiotics
which also belong to RiPPs66-71. These peptides possess a characteristic macrocyclic core that
consists of a monoaza six-membered ring central to multiple thiazoles and dehydroamino
acids66, 67. Similar to bottromycin, many members in this family exhibit interesting activity against
various pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococci (VRE) 67. Figure 1.11 shows one example of Thiopeptides
called Thiostrepton.Thiostrepton was discovered by Donovick et al., who described its
antibacterial properties in 1955, but the biosynthesis of these compounds was unclear until
200968.
Figure 1.11:Structure of Thiostrepton.
The biosynthetic pathway for thiostrepton contains 21 ORFs. The TsrH geneencoding for
precursor peptide contains 58 amino acids, as shown is Figure 1.1268. The first 41 aa is the
leader peptide and the last 17 aa is the core peptide (IASASCTTCICTCSCSS). After the
INTRODUCTION
12
precursor is produced, TsrO and TsrM, which are dehydratase, catalyze the formation of
thiazole or thiazoline from every cysteine. After this step, a further three dehydratases, TsrJ,
TsrK and TsrS, convert all the serine into dehydroalanines. TsrN and TsrL are suggested to be
responsible for the hetero Diels-Alder cyclization. In 2010, tclM, a homologue of TsrL, was
shown to be responsible for the transannular heteroannulation at the core of this class of
molecules72.
Figure 1.12:Potential biosynthetic pathway to Thiostrepton (Figure from ref. 68).
1.2.3 Cyanobactins
Cyanobactins are small cyclic peptides that are RiPPs (Figure 1.13)73-78. They are mainly
produced by cyanobacteria living in symbioses, as well as terrestrial, marine or freshwater
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environments. These peptides possess intensive modifications, including azole/azoline rings, D-
sterocenters and, in some cases, prenyl groups75, 77. Many cyanobactins exhibit interesting
activity, such as antimalarial, antitumor and multidrug reversing activities, and potential to be
used as pharmaceutical leads73-75.
Figure 1.13:Examples of the structural diversity of Cyanobactins.
Patellamide is the most well-known compound of this family. It was first isolated in 1981 and
turned out to be produced by Prochloron didemni, a cyanobacterial symbiont of Lissoclinum
patella79-81. Patellamide shows moderate cytotoxicity and activity against multidrug-resistant
cancer cell lines. The biosynthetic pathway for Patellamide was determined after genome
sequencing of P. Didemi. The gene encoding the precursor peptide contains a leader peptide
and two core peptides (for patellamides A and C), as shown in Figure 1.1479-81. There is also a
protease recognition sequence before each core peptide and a N-terminal recognition sequence
with a length of four to five amino acids. In the first biosynthetic step, the Cydodehydratase patD
catalyzes the formation of dihydrothiazol or dihydrooxazol ring from Cys or Ser/Thr groups.
Subsequently, the protease patG truncates the C-terminal recognition sequence and cyclizes
the peptide backbone. patG is also responsible for the dehydrogenation of dihydrothiazol or
dihydrooxazol ring to thiazole or oxazole. patF has no function in the biosynthesis of
patellamides78, 80, 81.
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Figure 1.14:Potential biosynthetic pathway to patellamide A.
1.2.4 Proteusins
Proteusins, known previously as polytheonamides, were isolated from the marine sponge
Theonella swinhoei in 199482, 83. These compounds are extensively modified. Each is a 48 aa
peptide, but 19 different amino acids are nonproteinogenic84, 85. The modifications include an
unprecedented N-acyl moiety, many tert-leucines, C-methylated amino acids and, most
interestingly, a lot of D-amino acids (Figure 1.15). Proteusins were assumed for a long time to
be products of NRPS, which can generate peptides with unusual residues84, 85.
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Figure 1.15:Structure of polytheonamide (Figure from ref. 86).
However, in 2012, Freeman et al. identified a biosynthetic pathway that contains a precursor
peptide for polytheonamide by mining the sponge metagenome86. It turned out that this gene
cluster is from a bacterial endosymbiont of Theonella swinhoei. The gene cluster also contains
six other tailoring enzymes that carry out 48 different posttranslational modifications, which
makes polytheonamides the most extensively modified RiPPs known to date (Figure 1.16)40, 86.
It was proposed that after the precursor peptide is produced, PoyD, a single epimerase,
generates most, and possibly all, D-residues in the peptide. The second step in polytheonamide
biosynthesis is dehydration of a Thr residue by PoyF, which seems to be responsible for the
unusual N-acyl residue. Further conversion to the N-acyl unit is probably catalyzed by radical-
SAM methyltransferases (PoyB and/or C are candidates) 40, 86. PoyE, a single N-
methyltransferase, was shown to be responsible for the generation of eight N-methylated Asn
residues. The functions of other proteins in the gene cluster have been elusive so far40, 86.
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Figure 1.16: Biosynthetic pathway to polytheonamide.
1.2.5 Sactipeptides
Sactipeptides are a new growing class of RiPPs that show diverse bioactivities (Figure 1.17)87-90.
The characteristic structure of a sactipeptide is an intramolecular thioether bond that crosslinks
the sulfur atom of a cysteine residue with the a-carbon of another residue40, 87-90. The first
compound of this family, subtilosin A, was isolated from Bacillus subtilis 168 in 1985. The three-
dimensional solution structure of subtilosin A was solved by NMR in 200391-94.
Figure 1.17:Examples of the structural diversity of sactipeptides (Figure from ref. 87).
Most of the sactipeptides isolated thus far show some antimicrobial activity. Another example is
the sporulation killing factor (SKF) produced by Bacillus subtilis, which plays a key role in
sporulation89, 95, 96. It is interesting that most of these compounds only have a narrow specificity
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of antimicrobial activity, which suggests that these peptides require recognition of a specific
receptor molecule in the target organisms40, 87, 91, 92, 95, 96.
Figure 1.18: Biosynthetic pathway to subtilosin A (Figure from ref. 90).
Several gene clusters responsible for the biosynthesis of sactipeptides have been reported
(Figure 1.18)87-90. It has been shown for the biosynthesis of subtilosin A that the characteristic
sulfur to a-carbon crosslink was generated by a single radical SAM enzyme AlbA. Other cases,
such as SKF and thurincin, also use an AlbA homology enzyme to generate the unusual sulfur
bridge87-90.
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1.3 Lasso peptides
Lasso peptides are a growing family of intriguing RiPPs40, 97-99. They contain about 20 residues
and the characteristic structure of these molecules is a unique interlocked topology that involves
an N-terminal seven- to nine-residue macrolactam ring where the C-terminal tail is threaded,
stabilizing the entropically disfavored lasso structure40, 97-99. The first lasso peptide was
discovered in 1991. Since then, more than 40 lasso peptides have been described97.
1.3.1 Classification of lasso peptides
Lasso peptides normally use bulky amino acids located in the tail below and above the ring to
trap the tail. However, they also sometimes use a disulfide bridge to further stabilize the
structure. Therefore, lasso peptides are subdivided into three subtypes, depending on the
absence (class II) or presence of one (class III) or two (class I) disulfide bridges (Figure 1.19)100.
Figure 1.19: Three classes of lasso peptide. Siamycin as an example of a class I lasso peptide (Protein Data Bank
[PDB]: 1RPB); BI 32169 is the only class III lasso peptide (PDB: 3NJW); Mccj25 is an example of a class II lasso
peptide (PDB: 1Q71).
Class I lasso peptides have two disulfide bonds: one between the N-terminal cysteine and the
loop, and the other between the ring and the tail. Currently, there are four examples of class I
lasso peptides which have been investigated. It was shown in the biosynthesis of Sviceucin that
no gene was involved in the biosynthesis of the disulfide bonds. There is only one example of a
class III lasso peptide called BI-32169. This lasso peptide contains a single disulfide bond
between a cysteine at the C-terminus of the peptide and the ring. Most of the lasso peptides
isolated belong to class II, which lacks disulfide bonds100. There are 33 examples of class II
lasso peptide, which are summarized in Table 1.1. Most of them were discovered after 200897, 98.
Table1.1:Overview of all known lasso peptides sorted by class.
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Name Sequence Host strain
ClassI
RP 71955/aborycin CLGIGSCNDFAGCGYAVVCFW Streptomyces sp.
Siamycin I/MS-271/NP-06 CLGVGSCNDFAGCGYAIVCFW Streptomyces sp.
Siamycin II CLGIGSCNDFAGCGYAIVCFW Streptomyces sp.
Sviceucin CVWGGDCTDFLGCGTAWICV Streptomyces sviceus
ClassII
Anantin GFIGWGNDIFGHYSGDF Streptomyces coerulescens
Capistruin GTPGFQTPDARVISRFGFN Burkholderia thailandensis
Lariatin A GSQLVYREWVGHSNVIKP Rhodococcus sp. K01-B0171
Lariatin B GSQLVYREWVGHSNVIKPGP Rhodococcus sp. K01-B0171
Microcin J25 GGAGHVPEYFVGIGTPISFYG Escherichia coli AY25
Propeptin GYPWWDYRDLFGGHTFISP Microbispora sp. SNA-115
RES-701-1 GNWHGTAPDWFFNYYW Streptomyces sp. RE-701
SRO15-2005 GYFVGSYKEYWSRRII Streptomyces roseosporus
Astexin-1 GLSQGVEPDIGQTYFEESRINQD Asticcacaulis excentricus CB 48
Astexin-2 GLTQIQALDSVSGQFRDQLGLSAD Asticcacaulis excentricus CB 48
Astexin-3 GPTPMVGLDSVSGQYWDQHAPLAD Asticcacaulis excentricus CB 48
Caulosegnin I GAFVGQPEAVNPLGREIQG Caulobacter segnis
Caulosegnin II GTLTPGLPEDFLPGHYMPG Caulobacter segnis
Caulosegnin III GALVGLLLEDITVARYDPM Caulobacter segnis
Sungsanpin GFGSKPIDSFGLSWL Streptomyces sp.
Burhizin GGAGQYKEVEAGRWSDRIDSDDE Burkholderia rhizoxinica HKI454
Caulonodin I GDVLNAPEPGIGREPTGLSRD Caulobacter sp. K31
Caulonodin II GDVLFAPEPGVGRPPMGLSED Caulobacter sp. K31
Caulonodin III GQIYDHPEVGIGAYGCEGLQR Caulobacter sp. K31
Zucinodin GGIGGDFEDLNKPFDV Phenylobacterium zucineum HLK1
Rhodanodin GVLPIGNEFMGHAATPGITE Rhodanobacter thiooxydans LCS2
Rubrivinodin GAPSLINSEDNPAFPQRV Rubrivivax gelatinosus IL44
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Sphingonodin I GPGGITGDVGLGENNFGLSDD Sphingobium japonicum UT26
Sphingonodin II GMGSGSTDQNGQPKNLIGGISDD Sphingobium japonicum UT26
Syanodin I GISGGTVDAPAGQGLAGILDD Sphingobium yanoikuyae XLDN2-5
Sphingopyxin I GIEPLGPVDEDQGEHYLFAGGITADD Sphingopyxis alaskensis RB2256
Sphingopyxin II GEALIDQDVGGGRQQFLTGIAQD Sphingopyxis alaskensis RB2256
streptomonomycin SLGSSPYNDILGYPALIVIYP Streptomonospora alba
Chaxapeptin GFGSKPLDSFGLNFF Streptomyces leeuwenhoekii C58
Xanthomonin I GGPLAGEEIGGFNVPG Xanthomonas gardneri
Xanthomonin II GGPLAGEEMGGITT Xanthomonas gardneri
Xanthomonin III GGAGAGEVNGMSP Xanthomonas citri
Lassomycin GLRRLFADQLVGRRNI Lentzea kentuckyensis
ClassIII
BI-32169 GLPWGCPSDIPGWNTPWAC Streptomyces sp.
1.3.2 Function of lasso peptides
Lasso peptides were discovered prior to 2008 in the course of activity-driven compound
isolations. Their activities include antimicrobial, anti-viral and anti-metastatic activity101-108.
Others also function as receptor antagonists, enzyme inhibitors and so on (Table 1.2)40, 97-100, 109,
110. However, the activity of most of the lasso peptides discovered since 2008 through genome
mining are still unknown. They are isolated mainly from Proteobacteria, and their biosynthetic
gene clusters lacks an immunity-conferring ABC-transporter99, 111-118. These lasso peptides are
believed to function as a type of scavenging molecule113, 118. In addition to the native bioactivity,
lasso peptides can also be promising molecular scaffolds for epitope grafting. In the case of
Mccj 25, it has an unusually long loop that could be used for drug design. The integrin-binding
motif RGD was recently successfully grafted onto Mccj25 by substituting a tripeptide sequence
in the loop region with Arg-Gly-Asp119. The Mccj 25-RGD displayed nanomolar affinity towards
avβ3, avβ5, a5β1, and aIIbβ3 integrins. An optimization of a grafted lasso peptide, named
MccJ25(RGDF), was recently shown to be a highly potent and selective αvβ3 integrin inhibitor120.
Table1.2:Biological activities of known lasso peptides
Name Inhibitor/ antagonist of Antimicrobial activity
Anantin atrial natriuretic factor -
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BI-32169 glucagon receptor -
Capistruin Gram-negative RNA polymerase Yes
Lariatin Yes
Lassomycin ClpC1 Yes
Microcin J25 Gram-negative RNA polymerase Yes
Propeptin prolyl endopeptidase Yes
RES-701 type endothelin type-B receptor -
Siamycin type HIV fusion and replication,
myosin light chain kinase
Yes
streptomonomycin - Yes
Chaxapeptin lung cancer cell line -
Sungsanpin lung cancer cell line -
1.3.3 Biosynthesis of lasso peptides
Lasso peptides have thus far only been isolated from Proteo- and Actinobacterial sources40, 97-99.
The biosynthetic gene cluster for lasso peptide could be classified into three classes prior to the
research carried out in this work40, 97-99. The biosynthesis of the Mccj 25 lasso peptide
represents one class and has been well studied in the past101-103, 121-126. This biosynthetic cluster
contains four genes: mcjA encodes the precursor peptide, mcjB is an ATP-dependent cysteine
protease, mcjC is an ATP-dependent asparagine synthetase homologue and mcjD is an ABC
transporter. While McjD is only needed to export the mature antimicrobial compound, McjB and
McjC participate directly in the maturation of McjA into MccJ25101-103, 121-126. Other examples
belonging to this family include Capistruin127. There is another class of lasso peptide gene
cluster which also contains an ABC-transporter, but the B protein is split into two separate
ORFs homologous to the N- and C-terminal domains of McjB. Examples of members of this
family includes lariatin, lassomycin, streptomonomicin, sviceucin and chaxapeptin104-108, 128.
They are mainly isolated from Actinobacteria. Regarding Astexin and other recently new
isolated lasso peptides from Proteobacteria, the gene clusters lack an ABC-transporter and
instead feature other highly conserved adjacent genes, such as putative peptidases, which have
recently been shown to act as lasso peptide-specific isopeptidases (Figure 1.20)99, 111-118.
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Figure 1.20: Biosynthesis of Lasso peptide. (A) Three types of biosynthetic gene cluster for lasso peptide. (B)
Scheme of the suggested mechanism of lasso peptide biosynthesis. (C) Isopeptidase linearizes the folded lasso
peptides ( Figure from ref 113).
1.3.4 Discovery of lasso peptides
All the lasso peptides found before 2008 were discovered in the course of activity-driven
compound isolations. Some lasso peptides, such as lassomycin, sungsanpin and
streptomonomycin, were also discovered in the same way after 200897, 104, 105, 107. A genome
mining method was applied in 2008 to discover new lasso peptides. As a result, capistruin was
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isolated and showed moderate antimicrobial activity127. After this example, the same method
was applied and a lot of lasso peptides lacking any bioactivity were isolated from
Proteobacterial sources, including caulosegnin, xanthomonin and rubrivinodin111, 112, 114-116. Link
et al. developed a precursor-centric genome-mining approach for lasso peptide discovery and
several lasso peptides from Proteobacteria including astexin were found117. They also
discovered that these lasso peptides are produced by a lasso peptide gene cluster featuring a
lasso peptide Isopeptidase113, 118. Except for all the methods mentioned above, a mass
spectrometry-guided genome mining approach was also applied for lasso peptide discovery42.
This led to the discovery of sviceucin and SRO15-2005 lasso peptide42, 108. All the genome
mining methods are generally powerful in lasso peptide discovery, but the bioactivity of these
compounds is still elusive.
1.4 Aim of this work
The aim of this thesis was to further exploit the lasso peptide biosynthetic system. All the lasso
peptides were isolated from either Proteobacterial or Actinobacterial sources97-99, 112. Lasso
peptides from Firmicutes have not been reported previously. Thus, the first part of this thesis
was an attempt to isolate the first lasso peptide, paeninodin, from Firmicutes. The lasso peptide
was successfully heterologously expressed in E. coli and the topology of the lasso peptide was
proved by MS2, ion mobility-mass spectrometry (IM-MS) and stability studies.
Bioinformatics analysis showed that the lasso peptide gene clusters from Firmicutes have an
unusual CAKB1B2D organization, which is different from the gene clusters from Proteobacteria
and Actinobacteria. It contains not only the conserved genes encoding the precursor peptide, B,
C protein, and ABC-transporter, but an additional gene coding for a putative kinase. So far,
descriptions of lasso peptide tailoring in the literature are notably rare (examples include C-
terminal methylation of lassomycin and Trp hydroxylation of some RES-701 family lasso
peptides)104. Therefore, the second part of this thesis investigates the role of the unusual kinase
in the gene cluster. We successfully isolated a phosphorylated lasso peptide by heterologous
expression of the whole gene cluster in E. coli. We identified the kinase by knock-out and in
trans experiments as a novel tailoring enzyme for lasso peptide for the first time.
The third part of the thesis investigates how the kinase tailors the lasso peptide. We clearly
showed by in vitro experiment that the kinase first modified the precursor peptide and then the
modified precursor peptide was transformed into a modified lasso peptide. Moreover, a
plausible catalytic mechanism for the kinase is proposed based on mutagenesis studies. Finally,
it could be unambiguously determined by substrate specificity studies and estifrication assays
combined with NMR studies that this kinase exclusively transfers a phosphate group from ATP
to the side chain of the C-terminal Ser. This thesis reveals how lasso peptides are chemically
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diversified and establishes the foundation for rational engineering. The main results of this
thesis were published in The Journal of Biological Chemistry (JBC)129.
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2. Material
2.1 Equipments
Table 2.1: List of devices used in this work.
Device manufacturer and type
Analytical balance Sartorius
Autoclave Tuttnauer 5075 ELV, Fedegari Autoclavi SPA FVA3/A1
Centrifuges Sorvall RC 5B Plus and RC6+ (SS‐34,
SLC‐300,SLC‐4000 rotors),
Heraeus Minifugue RF and Megafugue 1.0R, Eppendorf
5415 D, 5415 Rand 5702 R
Clean-Bench Antair BSK
Documentation system
for DNA‐electrophoresis
gels
Cybertech CS1 camera, Mitsubishi video copy thermo
printer
Electrophoresis chamber Agarose gel chambers manufactured in-house (PUMa,
Marburg), Bio-Rad Mini-PROTEAN 3 gel chamber
Electroporation Bio-Rad Gene-Pulser II
Fast protein liquid
chromatography (FPLC)
Amersham Pharmacia Biotech Äktaprime and Äktapurifier:
(pH/C-900,UV-900, P-900 and Frac-900 modules)
French-Press SLM Aminco French-Pressure Cell Press 5.1, Thermo
SpectronicStandard Cell 40 KP
LTQ-FT-ICR-MS Thermo Fischer Scientific
HPLC-systems Agilent series 1100 (HPLC-system withvacuum degasser,
quarternary pump, auto samplerpreparative fraction
collector, column thermostat, HP-ChemStationsoftware)
HPLC-MS-System (High
Resolution)
Thermo Fisher Scientific LTQ-FTAgilent 1100 HPLC
system:Vacuum degasser, DAD detector, quaternary pump,
autosampler
HPLC-MS-System Hewlett-Packard MSD 1100Agilent 1260 HPLC system:
Vacuum degasser, DAD detector, quaternary
pump,autosampler, fraction collector
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Device manufacturer and type
Incubators New Brunswick Scientific Series 25, Innova 4300 Shaker,
Infors HTMultitron II and Unitron
Lyophilizer Christ Alpha 2-4 LSC
NMR Bruker AV600
pH meter Schott CG 840
Nanodrop-Photometer PEQLab ND-1000
Pipettes Eppendorf Research series
Spectrophotometer PEQLab Nanodrop ND-1000; Pharmacia Ultrospec 3000
Thermal cycler Eppendorf Mastercycler Personal
Thermomixer Eppendorf Thermomixer comfort
Vortexer Scientific Industries VortexGenie2
Water deionizer Seral Seralpur Pro90CN
2.2 Chemicals, enzymes and consumables
All chemicals not listed in Table 2.2 were purchased from Sigma-Aldrich (Steinheim, Germany),
Fluka (Steinheim, Germany) or Merck (Darmstadt, Germany) in p.a. quality and were used
without further purification.
Table 2.2: Chemicals, enzymes and general materials and consumables.
Manufacturer Products
Applichem (Darmstadt, Germany) ampicillin, kanamycin, media components
Biomol (Ilvesheim, Germany) DTT
Eppendorf (Hamburg, Germany) 1.5 and 2.0 mL reaction tubes
Eurogentech (Seraing, Belgium) agarose, electroporation cuvettes
GE Healthcare (Freiburg, Germany) IPTG, FPLC Ni-NTA and Superdex 200 5/150
GL SEC columns, yeast extract, aldolase,
ovalbumin, ribonuclease, aprotinin protein
standards
Invitrogen (Karlsruhe, Germany) E. coli strains (BL21, TOP10)
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Manufacturer Products
Macherey & Nagel (Düren,Germany) C18-HPLC columns (Nucleosil, Nucleodur)
Macherey-Nagel (Düren, Deutschland) 125/2 Nucleodur 100-3 C18ec, 250/12
Nucleodur C18ec, 250/4.6 Nucleodur C18
HTec
Merck Biosciences - Novagen
(Nottingham, UK)
pET Vector
Millipore (Schwalbach, Germany) Dialysis membranes (pore size: 0.025 μM),
Amicon Ultra‐15 concentrators
New England Biolabs (Frankfurt,
Germany)
desoxyribonucleotides (dATP, dTTP, dGTP,
dCTP), DNA markers, protein size markers,
restriction endonucleases,Phusion Hi-Fidelity
DNA polymerase, T4 DNA ligase
Oxoid (Cambridge, UK) agar nr. 1, tryptone
QIAgen (Hilden, Germany) QIAquick Gel Extraction kit, Ni-NTA IMAC
resin
Sarstedt (Nümbrecht, Germany) Pipette tips, Falcon tubes (15 and 50 mL)
Schleicher & Schüll (Dassel,
Germany)
Sterile filters (0.20 and 0.45 μm), Whatmann-
3MM paper
2.3 Oligonucleotide
Oligonucleotide primers used in this work are summarized in Table below.They are used either
for the amplification of target genes or for specific mutagenesis.
Table 2.3.Primers used for cloning of the padeCAKB1B2D gene cluster. Genomic DNA of P. dendritiformis C454 was
used as a template for PCR. Introduced restriction sites are underlined.
construct name sequence
pET41a-
padeCAKB1B2D
Pade_C_NdeI_FP GG GAATTC CATATG GGT GCAGTAGCAGGC
ATT TATCAC CTT CAA CAC G
Pade_D_XhoI_RP AT ATCTC GAG CTA CAG CGT ATA GAC GTT AAC
AGG CTG CGC CTC
Table 2.4. Primers for mutagenesis of the padeCAKB1B2D gene cluster and cloning of the padeK gene. All mutations
were introduced using SLIM. SLIM overhang regions are underlined. Mutated positions are highlighted in bold.
pET41a-padeCAKB1B2D was used as template for all PCR reactions. Primers P1 and P2 were used in several PCR
reactions.
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constructs name sequence
pET41a-
padeCAB1B2D
Pade_deHpr_P1 AGTTTGTAAAATGAGAACAGGGGAACCCTTATACCCGTTG
Pade_deHpr_P2 CCGGCAAGGAGAGAATGACCAATGAGCAAAC
Pade_deHpr_P3 GTAATGTTTCTCTCCAAGAGTTTGTAAAATGAGAACAGGGGAAC
Pade_deHpr_P4 CTTGGAGAGAAACATTACCCGGCAAGGAGAGAATGAC
pET41a-
padeCAKB1B2D(
H20A)
Pade H20A P1 GTCTTCATCCGGGTCCGGCTGGAAAGCATC
Pade H20A P2 ACAATTGGCTTAATGAATGCGGTTACTGGTG
Pade H20A P3 CTAGCTATCGTACGCCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade H20A P4 GTGGCGTACGATAGCTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
Y21A)
Pade Y21A P3 CTAGCTATCCGCATGCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade Y21A P4 GTGCATGCGGATAGCTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
Y21F)
Pade Y21F P3 CTAGCTATCAAAATGCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade Y21F P4 GTGCATTTTGATAGCTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
D22A)
Pade D22A P3 CTAGCTCGCGTAATGCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade D22A P4 GTGCATTACGCGAGCTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
S23A)
Pade S23A P3 CTACGCATCGTAATGCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade S23A P4 GTGCATTACGATGCGTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
S23)
Pade de1 P2 ATTGGCTTAATGAATGCGGTTACTGGTGCGGTAC
Pade de1 P3 TGTCTAATCGTAATGCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade de1 P4 GTGCATTACGATTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
D22 S23)
Pade de2 P2 GGCTTAATGAATGCGGTTACTGGTGCGGTAC
Pade de2 P3 AATTGTCTAGTAATGCACGTCTTCATCCGGGTCCGGCTGGAAAG
Pade de2 P4 GTGCATTACTAGACAATTGGCTTAATGAATGCGGTTAC
pET41a-
padeCAKB1B2D(
T-2A)
Pade T-2A-P1 AACATCCAACACTTCAAGGGACGGCTTGCTGTACTGCTTTTTC
Pade T-2A-P2 GGTACCTCTACCCCGGATGCTTTCCAGCCGGACCCG
Pade T-2A-P3 CGGGCCAGCCATCGCCTGATGAACATCCAACACTTCAAGGGAC
Pade T-2A-P4 CATCAGGCGATGGCTGGCCCGGGTACCTCTACCCCGGATG
pET41a-
padeCAKB1B2D(
T-2C)
Pade T-2C-P3 CGGGCCAGCCATGCACTGATGAACATCCAACACTTCAAG GGAC
Pade T-2C-P4 CATCAGTGCATGGCTGGCCCGGGTACCTCTACCCCGGATG
pET41a-
padeCAKB1B2D(
T-2V)
Pade T-2V-P3 CGGGCCAGCCATCACCTGATGAACATCCAACACTTCAAGGGAC
Pade T-2V-P4 CATCAGGTGATGGCTGGCCCGGGTACCTCTACCCCGGATG
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pET41a-
padeCAKB1B2D(
A1C)
PadeA1C-P3 CGGGCCGCACATGGTCTGATGAACATCCAACACTTCAAGGGAC
PadeA1C-P4 CATCAGACCATGTGCGGCCCG GGTACCTCTACCCCGGATG
pET41a-
padeCAKB1B2D(
A1G)
PadeA1G-P3 CGGGCCGCCCATGGTCTGATGAACATCCAACACTTCAAG GGAC
PadeA1G-P4 CATCAGACCATGGGCGGCCCG GGTACCTCTACCCCGGATG
pET41a-
padeCAKB1B2D(
A1S)
PadeA1S-P3 CGGGCCGCTCATGGTCTGATGAACATCCAACACTTCAAGGGAC
PadeA1S-P4 CATCAGACCATGAGCGGCCCGGGTACCTCTACCCCGGATG
pET41a-
padeCAKB1B2D(
D9E)
PadeD9E-P1 AGGTACCCGGGCCAGCCATGGTCTGATGAACATCCAACAC
PadeD9E-P2 GCCGGACCCGGATGAAGACGTGCATTACGATAGCTAGAC
PadeD9E-P3 TGGAAAGCTTCCGGGGTAGAGGTACCCGGGCCAGCCATGG
PadeD9E-P4 CTACCCCGGAAGCTTTCCAGCCGGACCCGGATGAAGACGTG
pACYC-padeK
PadeK-NdeI-FP GGAATTCCATATGACCGAACGAGCAGCGGTAAG
PadeK-XhoI-RP CCGCTCGAGCATTGGTCATTCTCTCCTTGC
pACYCD-NdeI GGAATTCCATATGTATATCTCCTTATTAAAGTTAAAC
pACYCD-XhoI CCGCTCGAGTCTGGTAAAGAAACCGCTGC
Table 2.5.Primers for cloning of padeK and thcoK. Overhang regions for Gibson Assembly are highlighted in bold.
Introduced restriction sites are underlined.
constructs name sequence
pETMBP-padeK
pETMBP-PadeK-
NdeI-FP
GGAATT CCA TAT GAC CGAACG AGCAGC GGT
AAG
pETMBP-PadeK-
XhoI-RP
CCG CTC GAG TCATTG GTC ATT CTC TCC TTG C
pET41-thcoK
KinaseThco FP ACTTTAAGAAGGAGATATACATATGA CCAGGA
CAAATACCG GCTATC GGTACC GGG CCT TC
KinaseThco RP GGTGGTGGTGGTGGTGCTCGAGTCG GCT CAC
CTC CCC ATC GGCATG CGT CTC TAT G
Table 2.6.Primers for cloning of the padeA gene into pET-48b(+). Overhang regions for Gibson Assembly are
highlighted in bold.
constructs name sequence
pET48b-padeA
PadeA V FP CTC GAG GCT TAATTAACC TAG GCT GCTAAA
CAAAGC C
PadeA V RP GGG TCC CTGAAAGAG GAC TTC AAGAGC CGC
G
PadeA FP AAGTCCTCTTTCAGGGACCC ATGAAAAAG CAG
TAC AGCAAG CCG TCC CTT GAAGTG
PadeA RP CCATGGGACGGTGTAAACGGTCATCGGCTCACCT
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C CCCATCGGCATGCGTCTCTATG
Table 2.7. Primers for exchanging padeK with thcoK in the pET41a-padeCAKBBD gene cluster. Overhang regions for
Gibson Assembly are highlighted in bold.
construct name sequence
pET41a-padeCA-
thcoK-
padeB1B2D
ThcoKexc V-FP CCGTTTACACCGTCCCATGGTTGGATTCAGCACGC
TTGATC
ThcoKexc V-RP GCTCATCTCTCCAAGAGTTTGTAAAATGAGAACAG
G GGAACC CTT ATACC
ThcoKexc K-FP CAAACTCTTGGAGAGATGAGCATGACCAGGACAA
ATACCG GCTATC GGTACC GGG CCT TC
ThcoKexc K-RP CCATGGGACGGTGTAAACGGTCATCGGCTCACCT
C CCCATCGGCATGCGTCTCTATG
Table 2.8.Primers for the mutagenesis of padeK and thcoK. All mutations were introduced using SLIM. SLIM
overhang regions are highlighted in bold. pET41a-padeCAKB1B2D and pET41a-padeCA-thcoK-padeB1B2D were
used as templates for padeK and thcoK mutations, respectively.
constructs name sequence
pET41a-
padeCAKB1B2D
_padeK(D161A)
PadeK D161A P1 CAG CGGATATCC CTC GGACAC CAG GTG CAA
GG
PadeK D161A P2 CCC GTC GTG ATGACT CAAGGC TCT CCT TGG
GTT G
PadeK D161A P3 AATAACATCCGCGCT AAG CAG CGGATATCC
CTC GGACAC CAG
PadeK D161A P4 CTTAGCGCGGAT GTTATT CCC GTC GTG ATG
ACT CAAGGC TCT CCT TG
pET41a-
padeCAKB1B2D
_padeK(D162A)
PadeK D162A P3 AATAACCGCATC GCT AAG CAG CGGATATCC
CTC GGACAC
PadeK D162A P4 CTTAGCGATGCGGTT ATT CCC GTC GTGATGACT
CAAGGC TCT CCT TG
pET41a-
padeCAKB1B2D
_padeK(D161A
D162A)
PadeK
D161AD162A P3
AATAACCGCCGCGC TAA GCAGCG GATATC CCT
CGGACA CCAG
PadeK
D161AD162A P4
CTTAGCGCGGCGGTTATT CCC GTC GTG ATGACT
CAAGGC TCT CCT TG
pET41a-
padeCAKB1B2D
_padeK(H123A)
PadeK H123A P1 TAA TTT TGC GCT GCAGCAAGATAATGC CCA
TAC
PadeK H123A P2 CGTAGC TAT TGA CGG GAAGGC CTATGC CAT
TATC
PadeK H123A P3 GCGCTGCCCGCCAA AGG CAT AAT TTT GCG CTG
CAG CAAGATAAT GC
PadeK H123A P4 TGCCTTTGGCGGGC AGC GCC GTAGCTATT GAC
GGG AAG
pET41a-
padeCAKB1B2D
_padeK(K144A)
PadeK K144A P1 CGGATT CGC CGATAATGG CATAGG CCT TCC
CG
PadeK K144A P2 GGC CTT GCA CCT GGT GTC CGAGGGATATCC
G
PadeK K144A P3 AAGGTCGACGCGCC CGC CCC GGATTC GCC
GATAAT GGCATAG
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PadeK K144A P4 GGGCGGGCGCGTCG ACC TTG GCC TTG CAC
CTG GTG TCC GAG
pET41a-padeCA-
thcoK-
padeB1B2D_thc
oK(H119A)
ThcoK H119A P1 GATGCG CCG CTG CAG CAG GAG CGC GC
ThcoK H119A P2 GTG GCG CGC GAC GGG CGC GCATAC GCCATC
ThcoK H119A P3 GACGCTGCCCGCAAG CGG CAG GAT GCG CCG
CTG CAG CAG G
ThcoK H119A P4 CTGCCGCTTGCGGGCAGC GTC GTG GCG CGC
GAC GGG C
pET41a-padeCA-
thcoK-
padeB1B2D_thc
oK(K140A)
ThcoK K140A P1 CGATTC GCC GAC GAT GGC GTATGC GCG
ThcoK K140A P2 TCC GCG GCG CTG CTG GAA CGC GGATTC
ThcoK K140A P3 CATCGTCGACGCGCC CGC GCC CGATTC GCC
GAC GAT GG
ThcoK K140A P4 GGCGCGGGCGCGTCG ACG ATG TCC GCG GCG
CTG CTG GAAC
pET41a-padeCA-
thcoK-
padeB1B2D_thc
oK(D157A)
ThcoK D157A P1 ACG GAATCC GCG TTC CAG CAG CGC CGC
ThcoKD157A P2 GCCATC GTC TTC GATGAG CGC GGCACG C
ThcoK D157A P3 GGCGACGTCCGCCGT CAC CAG ACG GAATCC
GCG TTC CAG CAG C
ThcoK D157A P4 CTGGTGACGGCGGAC GTC GCC GCCATC GTC
TTC GAT GAG CG
pET41a-padeCA-
thcoK-
padeB1B2D_thc
oK(D158A)
ThcoK D158A P3 GGCGACCGCGTC CGT CAC CAG ACG GAATCC
GCG TTC CAG CAG
ThcoK D158A P4 CTGGTGACGGACGCGGTC GCCGCCATC GTC
TTC GAT GAG CGC G
pET41a-padeCA-
thcoK-
padeB1B2D_thc
oK(D157A
D158A)
ThcoK
D157AD158A P3
GGCGACCGCCGCCGT CAC CAG ACG GAATCC
GCG TTC CAG CAG C
ThcoK
D157AD158A P4
CTGGTGACGGCGGCGGTC GCCGCCATC GTC
TTC GAT GAG CGC G
Table 2.9.Primers for mutagenesis of pET48b-padeA. All mutations were introduced using SLIM. SLIM overhang
regions are highlighted in bold. pET48b-padeA was used as template for all PCR reactions.
constructs name sequence
pET48b-padeA-
Core
GP-PadeAcore P1 AAGAGGACTTCAAGAGCCGCGGAGTGATG
GP-PadeAcore P2 CCCCGGATGCTTTCCAGCCGGACCC
GP-PadeAcore P3 TAGAGGTACCGGGTCCCTGAAAGAGGACTTC
AAGAGCCGC
GP-PadeAcore P4 TCAGGGACCCGGTACCTCTACCCCGGATGCTTTC
CAGCCG
pET48b-
padeA(S23A)
GP-PadeA-S23A
P1
CACGTCTTCATCCGGGTCCGGCTGGAAAGC
GP-PadeA-S23A
P2
GCTTAATTAACCTAGGCTGCTAAACAAAGCCCG
AAAGG
GP-PadeA-S23A CTCGAGCTACGCATC GTAATGCACGTCTTCATC
CGGGTCCGGC
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P3
GP-PadeA-S23A
P4
CATTACGATGCGTAGCTCGAGGCTTAATTAACC
TAGGCTGCTAAACAAAG
pET48b-
padeA(7xA-
HYDS)
GP-PadeA-7xA-
HYDS P1
CTGGAAAGCATCCGGGGTAGAGGTACCCGG
GP-PadeA-7xA-
HYDS P2
CATTACGATAGCTAGCTCGAGGCTTAATTAACCTAG
G
GP-PadeA-7xA-
HYDS P3
CGCTGCCGCTGCTGCCGCTGCCTGGAAAGCATC
CGGGGTAGAGGTACCCGG
GP-PadeA-7xA-
HYDS P4
GCAGCGGCAGCAGCGGCAGCGCATTACGATAGC
TAGCTCGAGGCTTAATTAACCTAGG
pET48b-
padeA(3xA-S)
GP-PadeA 3xA-S
P1
CACGTCTTCATCCGGGTCCGGCTGGAAAGC
GP-PadeA 3xA-S
P2
GCTTAATTAACCTAGGCTGCTAAACAAAGCCCGAA
AGG
GP-PadeA 3xA-S
P3
CTCGAGCTAGCTTGCTGCCGCCAC GTC TTC ATC
CGG GTC CGG CTG GAAAGC
GP-PadeA 3xA-S
P4
GCGGCAGCAAGCTAG CTC GAG GCT TAATTA
ACC TAG GCT GCTAAA CAAAG
2.4 Vector
2.4.1 pET41a(+)
The expression vector pET41a(+) was used for the
production of recombinant proteins in E. coli. It was also
used for heterologous expression of the lasso peptide gene
cluster. This vector has an N-terminal GST (glutathione-S-
transferase) tag, which allows purification of target protein by
glutathione affinity chromatography and may increase the
solubility of the target protein. After the GST tag, there are a
His tag, thrombin cutting site, S • Tag and aenterokinase
cutting site. The vector also contains a C terminal His tag.
The cloned gene is under the control of lac operator and a T7
promoter. In E. coli BL21 which has the T7 RNA polymerase,
the expression of the gene can be induced with the addition of IPTG or lactose. The vector also
contains a kanamycin resistance gene KanR which was used as a selection marker. This vector
Figure 2.1: Physical map of pET41a(+).
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was used to clone the whole paeninodin lasso peptide gene cluster, the PadeK and ThcoK
Kinases. NdeI was chosed as a cutting site, so only a His tag was added at the C terminal of the
recombinant protein.
2.4.2 pACYDuet-1
The pACYDuet-1 vector was used for co-
expression of PadeK kinase with the lasso
peptide gene cluster without kinase. It has two
multiple cloning sites (MCS), which are both
under the control of lac operator and T7
promoter. The transcription is dependent on the
T7 polymerase and is inducible by IPTG or
lactose. The pACYDuet-1 has a different origins
of replication site and a different resistance
marker compared with pET41a(+). The vector
also contains a chloramphenicol resistance
gene CmR which was used as a selection
marker. Thus this vector could be co-
expression with pET41a(+). E. coli BL21 (DE3) was
used as a host for expression.
2.4.3 pET-48b(+)
pET-48b(+) was used for heterologous expression of
all kinds of precursor peptide. The vector has a
thioredoxin fusion tag at the N terminal. A tev
protease cutting site was inserted between the
thioredoxin fusion tag and the target protein.
Thioredoxin fusion tag was commonly used to
promote the solubility of its fusion partners.
Particularly it is suitable for expression of small
protein or peptide. The fusion tag could protect the
partner from degradation and facilitate the purification
by Ni-NTA affinity chromatography. The vector
contains a kanamycin resistance gene KanR which was
used as a selection marker. This vector was used for
Figuer 2.3: Physical map of pET-48b(+)
vector
Figure 2.2: Physical map of pACYC-Duet-
1 vector.
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expression of the precursor peptide PadeA and its analogues. E. coli BL21 (DE3) was used as
a host strain.
2.4.4 pETMBP-1a
pETMBP-1a vector was used for expression of PadeK kinase.
The vector has MBP (Maltose binding protein) fusion tag at the
N terminal. MBP fusion tag like thioredoxin fusion tag was
commonly used to promote the solubility of its fusion partners.
The MBP tag has a 6x his tag at N terminal, thus could be
purified by Ni-NTA affinity chromatography. Besides, the MBP
tag itself could also be served as an affinity tag for purification
by means of a maltose matrix. Between the MBP fusion tag
and the target protein, there is a Tev protease cutting site
which could be used to remove the tag. The tev protease
cutting site was changed to Hrv-3C protease cutting site in
some cases by mutagenesis. The vector contains a kanamycin resistance gene KanR which
was used as a selection marker. This vector was used for expression of the PadeK kinase. E.
coli BL21 (DE3) was used as a host strain.
2.5 Bacterial strains
2.5.1 Paenibacillus dendritiformis C454
Paenibacillus dendritiformis is a species of pattern-forming bacteria, which was first discovered
in 90's by Ben-Jacob's group. It is a social microorganism that could change its morphotype
under different environments. Moreover, the strain could produce self-toxins to inhibit sibling
colonies. Bioinformatics studies showed that the strain contains diverse natural products gene
clusters like NRPs, PKs and RiPPs. In this work it was cultivated for extracting chromosomal
DNA and homologous fermentation for lasso peptide production.
2.5.2 Thermobacillus composti KWC4
Thermobacillus composti KWC4 is a moderately thermophilic bacterium isolated from a
composting reactor. It could grow aerobically at 32-61 °C, with optimal growing occurring at 50
°C. The strain is moderately halotolerant and is able to grow at NaCl concentrations up to 4.4%
(w/v). The DNA G+C content of this strain is about 60%. This strain contains a lasso peptide
gene cluster that shows high similarity with the one from P. dendritiformis C454. Therefore, the
Figure 2.4: Physical map of pETMBP-1a
vector.
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kinase from this strain was used to replace the insoluble kinase from the paeninodin gene
cluster.
2.5.4 Escherichia coli TOP10
The E. coli TOP10 stored by our lab was used as a general host for cloning and plasmid
preparation. The genotype of this strain is: F-mcrA∆(mrr-hsdRMS-mcrBC) ɸ80lacZ∆M15
∆lacX74 recA1 araD139 ∆(ara-leu)7697 galU galKrpsL(StrR) endA1 nupG.
2.5.3 Escherichia coli BL21 (DE3)
The E. coli BL21(DE3), purchased from Invitrogen, was used as a general host for the
heterologous expression of T7 promoter-driven vectors. The stain contains the T7 RNA
polymerase gene which is controlled by the lacUV5 promoter. The T7 RNA polymerase is
expressed upon induction by IPTG which induces high level expression of target protein from
T7 promoter driven expression vectors.This strain is a derivative of E. coli B strain and lacks
both the lon protease and the ompT membrane protease which may degrade expressed
proteins. The genotype of this strain is: F-ompT gal dcm hsdSB(rB-mB-) λ(DE3).
2.6 Culture media
Culture media listed below were used for cultivation or fermentation of the bacterial strain. Solid
agar plates in some cases were prepared by adding 1.5% (m/w) agar. All media were sterilized
by autoclavation (121°C, 20 min). Antibiotics and other additional components were added after
sterile-filtration.
2.6.1 LB-Medium
The lysogeny-broth (LB) medium was used for cultivation of E. coli species in this work. An
exact composition is given in Table 2.10.
Table 2.10: Composition of LB medium used. The pH was adjusted to pH 7.0.
Component Concentration
yeast extract 5 g/L
tryptone 10 g/L
NaCl 5 g/L
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2.6.2 CASO Medium
The CASO medium was used for cultivation of P. dendritiformis. The DSMZ number of this
medium is 220. An exact composition is given in Table 2.11.
Table 2.11: Composition of CASO medium used. The pH was adjusted to pH 7.3.
Component Concentration
Peptone from casein 15 g/L
Peptone from soymeal 5 g/L
NaCl 5 g/L
2.6.3 Sulfolobus Medium
The Sulfolobus medium was used for cultivation of Thermobacillus composti KWC4. The DSMZ
number of this medium is 88. An exact composition is given in Table2.12.
Table 2.12: Composition of Sulfolobus medium used. The pH was adjusted to pH 7.0.
Component Concentration
(NH4)2SO4 1.3 g/L
KH2PO4 0.28 g/L
MgSO4 x 7 H2O 0.25 g/L
CaCl2 x 2 H2O 0.07 g/L
FeCl3 x 6 H2O 0.02 g/L
Allen’s trace element
solution (see below)
10ml/L
Yeast extract 1.0 g/L
Table 2.13: Composition of Allen’s trace element solution used. The pH was adjusted to pH 7.0.
Component Concentration
MnCl2 x 4 H2O 180mg/L
Na2B4O7 x 10 H2O 450mg/L
ZnSO4 x 7 H2O 22mg/L
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CuCl2 x 2 H2O 5mg/L
Na2MoO4 x 2 H2O 3mg/L
VOSO4 x 2 H2O 3mg/L
CoSO4 1mg/L
2.6.4 M9 Medium
M9 medium was used for the heterologous expression of lasso peptide gene cluster in E. coli as
a standard medium of the heterologous peptide Lasso fermentations. The asterisked sterile
stock solutions were added after autoclaving
Table 2.14: Composition of M9 medium used. The pH was adjusted to pH 7.0.
Component Concentration
Na2HPO4 · 12 H2O 17.1 g/L
KH2PO4 3.0 g/L
NH4Cl 1.0 g/L
NaCl 0.5 g/L
MgSO4(2 M) 1.0 ml/L
CaCl2(0.5 M) 0.2 ml/L
Glucose solution (40% w /
v) *
10.0 ml/L
Vitamin Mix (500x)* 0.2 ml/L
The 500x M9-vitamin mix was prepared from the following list. 10 M NaOH was added until all
components were dissolved. The solution was then filter sterilized and stored until use at 4 °C.
Table 2.15: Composition of Vitamin Mix used. The pH was adjusted to pH 7.0.
Component Concentration
choline chloride 1.0 g
folic acid 1.0 g
pantothenic acid 1.0 g
nicotinamide 1.0 g
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myo-inositol 2.0 g
pyridoxal hydrochloride 1.0 g
thiamine 1.0 g
riboflavin 0.1 g
disodium adenosine 5'-triphosphate 0.3 g
biotin 0.2 g
ad 300 mL
ddH2O
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3. Methods
3.1 Bioinformatic Methods
3.1.1 Genome mining of new lasso gene cluster by PSI-BlAST
The biosynthesis of Mccj25 has been well studied in the past121-123. The biosynthetic cluster for
Mccj25 contains four genes: mcjA encodes the precursor peptide; mcjB, an ATP-dependent
cysteine protease; mcjC, an ATP-dependent asparagine synthetase homolog; and mcjD, an
ABC transporter122. Among these four genes, mcjB homologs are found almost exclusively in
lasso peptide biosynthetic gene cluster, thus we used the B protein for genome mining studies.
The sequence of mcj25 (accession number YP_007443297.1) was downloaded from NCBI
(National Center for Biotechnology Information) and was applied in the position-specific iterated
basic local alignment search tool (PSI-BLAST) to start a homology search. The results of the
first round was then chosed as starting points for a further search run based on a position-
specific scoring matrix (PSSM). The following parameters were applied: maximum target
sequences of 500, expect threshold of 10 and PSI-BLAST threshold of 0.005. BLOSUM62
algorithm was used for judgment of amino acid similarity. With these settings, the PSI-BLAST
was repeated 4 times and provided the maximum number of results112.
All the identified B proteins were checked individually. About 10 Kb was downloaded from NCBI
and surrounding genes were analyzed for potential lasso peptide biosynthetic enzymes.
Potential ORFs were created and directly analyzed by the basic protein BLAST. The genes
which could be identified as an asparagine synthetase homolog were named as C protein. The
genes which could be identified as an ABC-transport were named as D protein. It is very often
to observe that a small protein (80-110 aa) is located beside the B protein which shows
homology to PqqD protein. We classified it as a B1 protein. The B protein in a B1 containing
lasso peptide gene cluster is thus renamed as a B2 protein. After the essential B and C protein
were assigned for lasso peptide gene cluster, small proteins of 40 to 70 aa length were tested
for their suitability as a possible precursor peptide. Generally, lasso peptides carry a Gly, Ala,
Cys, or Ser residue at position 1 and a ring-forming Glu or Asp residue at positions 7 to 9. A
conserved Thr at the penultimate position of the leader peptide was also highly conserved.
Based on these standards, the samll ORFs were checked by hand to see if they are suitable for
a precursor peptide.
3.1.2 Multiple sequence alignment
Multiple sequence alignment is a useful tool to identify conserved and variable regions in
homologous proteins. These results could be used to further map the relationship of protein
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sequences by generating phylogenetic tree and identify the evolution history of the target
protein. The multiple sequence alignments shown in this work were created by several different
tools. For generating phylogenetic tree of the kinases, ClustalX2 was used to do the multiple
sequence alignment. For multiple sequence alignment of the precursor peptides, CLC Main
Work bench was used.
3.1.3 Identification of conserved motifs with MEME algorithm
The kinase involved in the lasso peptide biosynthetic pathway is the first time reported and
represent a new family of serine kinase, thus it is necessary to search the conserved motifs of
the protein and gain some information about the catalytic mechanism. The Multiple EM for Motif
Elicitation (MEME:http://meme-suite.org/tools/meme) was used to identify the conserved
motits130. The parameters were set as follows. For the expected occurrence of motifs per
sequence is selected as 5. The minimum size of the conserved motifs is set to 6-50 aa.
3.1.4 Phylogenetic tree analysis
Protein sequences were retrieved from the gene clusters and aligned by CLUSTAL X2 with
standard settings as implemented in Mega 6. Phylogenetic trees were then constructed using
the minimum evolution and neighbor-joining method, and the Poisson-correction amino acid
model. Phylogeny was tested by bootstrapping with 1,000 replications. Phylogenetic trees were
constructed in this manner for both the C proteins and the kinases.
3.2 Molecular biology techniques
3.2.1 General strains maintenance
E. coli Top 10 and E. coli BL21(DE3) were mantained on LB-agar plates containing
corresponding antibiotic and incubated at 37 °C. Paenibacillus dendritiformis C454 was
maintained on CASO-agar plates at 30 °C. Thermobacillus composti KWC4 was maintained on
Sulfolobus-agar plates at 50 °C. Liquid cultures were incubated under continuous shaking at
200 rpm. Different antibiotics were added if necessary. For heterologous expression of the lasso
peptide, M9 medium was used for fermentation. For long-term storage, 20% (v/v) sterile glycerol
was added to a liquid culture and the resulting stocks were flash-frozen in liquid nitrogen and
stored at -80 °C until further use.
3.2.2 Preparation of genomic DNA from P. dendritiformis and T. composti KWC 4
Preparation of genomic DNA from P. dendritiformis and T. composti were done by a FastDNA®
SPIN Kit. 5 mL of liquid culture were harvested by centrifugation. The pellets were resuspended
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in 200 μL ddH2O. 1 mL CLS-TC lysis solution was then added. The mixture was then
homogenized in the FastPrep® Instrument for 40 seconds at a speed setting of 6.0 and
centrifuged at 14000 x g for 5-10 minutes. The supernatant was then transferred to a 2.0 mL
microcentrifuge tube and added an equal volume of Binding Matrix. The mixture was incubated
with gentle agitation for 5 minutes at room temperature on a rotator and half of the suspension
was transferred to a SPINTM filter and centrifuge at 14000 x g for 1 minute. Then add the
remaining suspension and centrifuge as before. 500μL prepared SEWS-M was added and the
pellet was gently resuspended using the force of the liquid from the pipet tip. Then centrifuge at
14000 x g for 1 minute and discard contents of catch tube. The tube was centrifuged a second
time at 14000 x g for 2 minutes to remove left ethanol and replace the catch tube with a new
tube. The DNA was eluted by gentally resuspending the binding matrix above the spin filter in
100 μL of DES and incubated for 5 minutes at 55 °C in a heat block. Centrifuge at 14000 x g for
1 minutes to bring eluted DNA into the catch tube. The DNA was stored at -20 °C until further
use.
3.2.3 PCR-based gene amplification and Vector construction
Generally, target genes were amplified from genomic DNA by PCR (polymerase chain reaction)
using the primers listed table 2.3-2.9. The Phusion High-Fidelity DNA Polymerase was used for
all PCR reactions. HF buffer and GC buffer combined with different concentration of DMSO
(2.5% or 5%) were used to screen optimum PCR conditions according to the manufacturer’s
manual. PCR products were purified from agarose gel slices with the QIAquick Gel Extraction
Kit (QIAGEN).
For vector construction, two different methods were used. One method is that the PCR products
and the plasmid are digested with restriction endonucleases and ligated with T4 DNA ligase.
Another method is that the vector and insert DNA are ligated with Gibson Assembly Master Mix
according to the manufacturer’s manual. Ligation products were dialyzed with a MF-Millipore
Membrane Filter and then transformed into E. coli TOP10 cells. Positive transformants were
selected on LB-agar plates and used for plasmid preparation. The right constructs were verified
by sequencing (GATC Biotech).
3.2.4 Preparation of electrocompetent E. coli cells
Both the E. coli Top 10 and E. coli BL21(DE3) electrocompetent cells were prepared by the
following protocol:
— 300 ml of LB medium was inoculated with 3 ml of an E. coli overnight culture
—incubate culture to an OD600 0.5-0.6 (37 °C, 200 rpm)
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—culture was transferred to 6 Falcon tubes (50 ml each) and centrifuge at 4000 rpm (4 °C，
20min)
—Pellets were resuspended twice with 40 ml of ice-cold, sterile ddH2O and then centrifuged
again (approx 25 min)
— Pellets were resuspended in 1 ml of ice-cold, sterile ddH2O and transferred into 2 ml
Eppendorf tubes, and centrifuge at 13,000 rpm (4 °C, 5 min)
—Pellets were resuspended in 500 µl 10% glycerol and then centrifuge (13000 rpm, 4 °C, 5
min).
—Pellets were resuspended in 200 µl 10% glycerol and a 40 µl in 1.5 mL Eppendorf tubes in
aliquots, flash-frozen in liquid nitrogen and stored at -80 °C until further use.
3.2.5 Preparation of plasmid DNA from E. coli
A single colony of E. coli carrying the right plasmid was inoculated into 5 mL fresh LB medium
(with matching antibiotic) and incubated overnight at 37 °C (200 rpm). All the culture was
centrifuged in a 2 mL Eppendorf reaction tube and wait for further use.
3.2.5.1 Quick and Dirty Plasmid Preparation
For the quick and dirty method, all the pellets were resuspended in 300 µl Buffer P1 (50 mM
Tris·HCl, 10 mM EDTA, 100 µg/L Rnase A, pH 8.0). Then 300 µl Buffer P2 (200 mM NaOH,
1%(w/v) SDS) was added and mixed by gently inverting the tube. The lysis was performed at
room temperature for 5 minutes. After that, 300 µl Buffer P3 (2.55 M KOAc, pH 4.8) was added
and mixed by gently inverting the tube again. The mixture was incubated on ice for 10 minutes
and centrifuged for 10 minutes (13000 rpm, 4 °C). The supernatant was transferred to a clean
1.5 mL Eppendorf reaction tube and mixed with 600 µl isopropanol. The components were
mixed by briefly inverting the reaction tube and centrifuged again (13000 rpm, 30 min, 4°C).
After centrifugation, the plasmid DNA will precipitate in the pellet. The supernatant was
discarded and the pellet was washed with 70% aq. ethanol and centrifuged again (13000 rpm,
10min, 4 °C). The supernatant was discarded and the pellet was dried at 37 °C. The pellet was
then dissolved in 100 µl ddH2O and the concentration was determined by Nanodrop. The
solution was then stored at -20 °C until further use.
3.2.5.1 GenEluteTM HP Plasmid Miniprep Kit
The HP GenElute Plasmid Miniprep Kit (Sigma-Aldrich) was used to prepare high purity plasmid
DNA for sequencing. By this method, the cell pellet was processed according to the
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manufacturer's instructions. The concentration was measured by Nanodrop and the DNA
solution was stored at -20 °C until further use.
3.2.6 SLIM-Mutagenesis
Mutations were introduced in a DNA sequence by the site-directed ligase independently
Mutagenesis (SLIM). All the primers used were listed in Table 2.3-2.9. All the PCR reactions
were performed using the Phusion Hi-Fidelity DNA polymeraseaccording to the manufacturer’s
manual.
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Figure 3.1: Schematic of the SLIM method. (A) For the SLIM method two different primer pairs (A and B) must be
used in two different PCRs. (B) products of both PCRs and schematic representation of the subsequent hybridization
reaction. The resulting plasmid, double-strand break can be transformed directly.
SLIM Mutagenesis, as the name implies, is a method that no ligation is needed for a
mutagenesis reaction131. This mehod is generally better than the round-the-horn site-directed
mutagenesis with high yield of correct construct. But one disadvantage of this method is that
two pairs of primers are needed in one mutation. The two forward and two reverse primers each
have the same annealing sequence, but differ in their 5 'overhang. The reverse and forward
primer carring a complementary 5 'overhang have at least 20 base pairs. To generate the
mutation, two PCR reactions were performed. The PCR products were treated with the
restriction enzyme DpnI according to the manufacturer (New England Biolabs) in order to
remove the methylated template plasmid DNA. The reaction mixture was then incubated at
80 °C for 20 minutes to inactive the DpnI enzyme. Subsequently, the so-called hybridization
reaction was performed. 10 µl of each PCR products were mixed and treated under the
following PCR conditions: 3 min 99 °C, 5 min 65°C, 40 min 30°C; the last two steps were
repeated three times. After the hybridization step, 10 µl of the reaction solution was dialyzed
with a MF-Millipore Membrane Filter and then transformed into E. coli TOP10 cells. Positive
transformants were selected on LB-agar plates and used for plasmid preparation. The right
constructs were verified by sequencing (GATC Biotech).
3.2.7 Preparation of expression constructs
All the right constructs verified by sequencing (GATC Biotech) were then retransformed into
electrocompetent E. coli BL21 (DE3) cells. Positive transformants were selected on LB-agar
plates with matching antibiotic. A single colony was picked for further expression.
3.3 Protein Chemical Method
3.3.1 Fermentation of P. dendritiformis C454 to produce paeninodin
For homologous fermentation of P. dendritiformis C 454, CASO Medium and M9 medium were
used. A total of 500 mL of each medium was inoculated with 5 mL of P. dendritiformis C454
overnight cultures and cultivated for 5 days at 30 °C.
3.3.2 Heterologous production of paeninodin in E. coli
For heterologous production of Paeninodin in E. coli, 600 mL M9 medium was used to screen
for the best fermentation conditions. pET41a-padeCAKB1B2D containing the lasso peptide
gene cluster was first retransformed into electrocompetent E. coli BL21 (DE3) cells. Positive
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transformants were selected on LB-agar plates with 50 µg/mL kanamycin. A single colony was
picked and 60 mL LB medium supplemented with 50 μg/mL kanamycin was inoculated with this
colony and grown overnight at 37 °C with shaking. From these cultures, 2 L baffled culture
flasks, containing 600 mL of M9 fermentation media each, were inoculated to OD600≈ 0.01. For
fermentation at 37 °C, IPTG (final concentration of 0.05 mM) was used to induce the expression
at OD600≈ 0.5-0.6. For fermentation at 20 °C, cells were first grown at 37 °C to OD600≈0.4-0.5 in
about 4.5 h, then slowly cooled down to 20 °C for another 1 h. At OD600≈ 0.5-0.6, the cells were
induced with IPTG (final concentration of 0.05 mM) and cultivated at 20 °C for 3 days.
3.3.3 Protein expression
3.3.3.1 Expression of PadeK kinase with pETMBPa-1 Vector
The expression of the PadeK kinase was facilitated by a maltose binding protein (MBP) phusion
tag. pETMBP-padeK was retransformed into electrocompetent E. coli BL21 (DE3) cells. Positive
transformants were selected on LB-agar plates with 50 µg/mL kanamycin. A single colony was
picked to make an overnight culture. Then 500 mL of LB medium in a 2 L baffled culture flasks
were inoculated to OD600≈ 0.01. The cells were grown at 37 °C to OD600≈ 0.4 in about 2 h. The
cells were then cooled down to 16 °C for another 1 h and induced with 0.05 mM IPTG for 16 h.
Cells were harvested by centrifugation (8000 rpm, 15 min, 4 °C), resuspended in 30 mL HEPES
buffer A (50 mM HEPES, 300 mMNaCl, 30 mM imidazole, 5% glycerol; pH 8.0) and stored at -
80 °C until further use.
3.3.3.2 Expression of ThcoK kinase with pET41a(+) Vector
For expression of the ThcoK kinase, pET41a(+) vector was used and A His6-tag was introduced
at the C-terminus of the kinase to facilitate the purification. Large-scale protein expression was
carried out in 10 times 600 mL LB medium. Initially, 60 mL LB medium (with 50 µg/mL
kanamycin) was inoculated with E. coli BL21(DE3) cells carrying the pET41-thcoK vector and
grown overnight at 37 °C with shaking. From this culture, 2 L baffled culture flasks containing
each 600 mL of LB medium was inoculated to OD600≈ 0.01. The cells were then grown at 37 °C
until the OD reach to 0.4 in about 2 h. The cells were then cooled down to 16 °C for another 1 h
and induced with IPTG (0.05 mM) for 16 h. Cells were harvested by centrifugation (8000 rpm,
15 min, 4 °C), resuspended in 30 mL HEPES buffer A (50 mM HEPES, 300 mMNaCl, 30 mM
imidazole, 5% glycerol; pH 8.0) and stored at -80 °C until further processing.
3.3.3.3 Expression of PadeA as thioredoxin fusion protein with pET-48b (+) vector
For the expression of the precursor peptide PadeA, a thioredoxin (Trx) fusion tag was used to
facilitate purification88. The plasmid pET48b-padeA was retransformed into electrocompetent E.
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coli BL21 (DE3) cells. The resulting E. coli BL21 (DE3) with pET48b-padeA strain was then
grown in LB medium containing kanamycin (50 µg/mL) at 37 °C with shaking for overnight.
Heterologous expression of the Trx-PadeA protein was carried out with the same protocol as
used for the kinases.
3.3.3.4 Expression of the Hrv3C protease
For the expression of the Hrv3C protease, a Glutathione S-transferase (GST) fusion tag was
used to facilitate purification. GST-tagged Hrv3C protease thus can be purified based on the
ability of GST to bind its substrate, glutathione (GSH).The Matrix (GSH Sepharose 4 Fast Flow)
of the column used (GSTPrep FF 16/10 20 mL (GE Healthcare)) contains covalently bound,
immobilized Glutathione which was used to bind the GST fusion proteins. After binding to the
column, the GST-fusion proteins were eluted from the column by using reduced glutathione.
Heterologous expression of the Hrv3C protein was carried out with the same protocol as used
for the kinases. Cells were harvested by centrifugation (8000 rpm, 15 min, 4 °C), resuspended
in 30 mL Lysis buffer A (50 mM Tris, 150 mMNaCl; pH 7.5) and stored at -80 °C until further
processing.
3.3.4 Cell disruption
For cell disruption, a French Press (SLM Aminco) was used. The components of the system
were put on ice to cold down. Meanwhile, the frozen cell suspension was thawed at room
temperature. The cells were then pressed through the Standard Cell (Thermo) and lysed 2-3
times. After that, the mixture was centrifuged (30min, 170000 rpm, 4 °C) to remove the insoluble
cell components. The supernatant was transferred to another clean tube and filtered for further
purification.
3.3.5 Protein purification
3.3.5.1 Purification of the PadeK kinase
The initially attempt to get soluble PadeK kinase was failed. Therefore, Maltose-binding protein
(MBP)-tag was used to increase the solubility of the PadeK kinase. Meanwhile, there is a 6x His
tag at the N terminal of the MBP tag which could facilitate the purification of the kinase. After the
purification, the MBP fusion tag could be removed by Hrv 3C protease. Thus, purification of
PadeK kinase took place in four stages. First, a Ni-NTA affinity chromatography was performed
and then a second size exclusion chromatography was performed using a Superdex 200 16/60
prep grade column. The pure proteins were then treated with Hrv3C protease. In the end, the
Hrv3C protease and the MBP phusion tag were removed by revise Ni-NTA affinity
chromatography. Pure padeK kinases were then obtained.
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Ni-NTA affinity chromatography was performed using an ÄKTA purifier system (Amersham
Pharmacia Biotech). A Ni-NTA column was equilibrated with buffer Hepes A (50 mM hepes,
300mM NaCl, 30 mM imidazole and 5% glycerol, pH 8.0) for 15 min with a flow rate of 1 mL/
min. Then the supernatant of the cell lysate (section 3.3.4) was applied to the column with a
flow rate of 1 mL/ min. The column was continued wash with 5 % buffer Hepes A2 (50 mM
hepes, 300mM NaCl, 250 mM imidazole and 5% glycerol, pH 8.0) for 10 min. Proteins were
then eluted using a linear gradient from 5 to 100% Hepes B buffer in 15 min at a flow rate of 1
mL/ min. The fraction size was 2 mL each. Purified proteins were identified by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), combined, concentrated and buffer
exchanged into Hepes buffer B (10 mM hepes, 150 mM NaCl, and 5% glycerol, pH 7.5) using
Amicon Ultra filters. Then a second size exclusion chromatography was performed using the
same FPLC system equipped with a Superdex 200 16/60 prep grade column equilibrated with
Hepe buffer B. The concentrated protein solution was then supplemented with Hrv-3C protease
(final concentration 0.1 mg/mL) to carry out the cleavage reaction at 4 °C for 16 h. Final
purification of PadeK was achieved by a reverse Ni-NTA affinity chromatography. The Ni-NTA
column was equilibrated with Hepes buffer A and after the sample had been applied, the pass
through proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), combined and concentrated. Pure protein fractions were flash-frozen in liquid
nitrogen and stored at -80 °C until further usage.
3.3.5.2 Purification of the ThcoK kinase
When we turned to the ThcoK kinase, we were pleasantly surprised to note that the ThcoK
kinase is extremely soluble. Therefore, a C terminal 6x his tag was added at the C terminus and
used to facilitate the purification. Thus for the purification of ThcoK kinase, a Ni-NTA affinity
chromatography was performed first and then a second size exclusion chromatography was
performed to obtain pure ThcoK kinase.
Ni-NTA affinity chromatography was performed using an ÄKTA purifier system (Amersham
Pharmacia Biotech). The Ni-NTA column was equilibrated with Hepes buffer A and after the
sample had been applied (flow rate 1 mL/min), proteins were eluted with increasing
concentrations of imidazole in Hepes buffer A. Purified proteins were identified by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), combined, concentrated and
buffer exchanged into Hepes buffer B (10 mM hepes, 150 mM NaCl, and 5% glycerol, pH 7.5)
using Amicon Ultra filters. Then a second size exclusion chromatography was performed using
the same FPLC system equipped with a Superdex 200 16/60 prep grade column equilibrated
with Hepe buffer B. Pure protein fractions were flash-frozen in liquid nitrogen and stored at -
80 °C until further usage. Notably, Even though the ThcoK kinase is super soluble, it tends to
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form aggregates with itself when temperature changed drastically. We handled this enzyme at
room temperature consistently.
3.3.5.3 Purification of the Trx-PadeA Phusion Protein
Thioredoxin fusion tag was used to facilitate the purification of PadeA precursor peptide.
Between the thioredoxin fusion tag and the PadeA peptide, there is a 6xHis tag which is used to
facilitate the purification and a Hrv 3C protease cutting site which is used to remove the tag by
treating with Hrv3C protease. Thus for the purification of Trx-PadeA Phusion protein, two steps
including a Ni-NTA affinity chromatography and a size exclusion chromatography were applied.
Generally, the Trx-PadeA phusion protein was purified using the same method as the ThcoK
kinase. The concentrated protein solution was then supplemented with Hrv-3C protease (final
concentration 0.1 mg/mL) to carry out the cleavage reaction at 4 °C for 16 h. Final purification of
PadeA was achieved by apreparative HPLC.
3.3.5.4 Purification of the Hrv 3C protease
Glutathione S-transferase (GST) is an enzyme found in most organisms. It consists of 220
amino acid residues and could be used as a fusion tag, making the tagged protein more soluble
as well as simplifying its purification and detection. The purification of GST-tagged protein is
based on the high affinity of GST for glutathione (GSH). When applied to the affinity medium,
GST-tagged proteins bind to the glutathione ligand, and impurities are removed by washing with
binding buffer. Tagged proteins are then eluted from the chromatography medium by using the
solublereduced glutathione. The purity of the protein after purification is over 90% due to the
high specificity of GSH to GST.
Table3.1: Composition of Buffer used for purification of Hrv3C protease
lysis buffer Wash buffer Elution buffer Storage buffer
50 mM Tris pH=8.0 50 mM Tris pH=8.0 50 mM Tris pH=8.0 50 mM Tris pH=7.5
1 M NaCl 1 M NaCl 1 M NaCl 150 M NaCl
1 mM EDTA 1 mM EDTA 1 mM EDTA 10 mM EDTA
1 mM DTT 1 mM DTT 1 mM DTT 1 mM DTT
10% protease
inhibitor
10 mM reduced
glutathione
20% glycerol
Benzonase
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For the purification of the Hrv-3C protease with a GST-tag, The GSTPrep FF16/10 column was
equilibrated with wash buffer for 15 min with a flow rate of 1 mL/ min (Table 3.1). Then the cell
lysate was applied to the column with a flow rate of 1 mL/ min. The column was continued wash
with wash buffer for 10 min. Proteins were then eluted using elution buffer at a flow rate of 1 mL/
min. The fraction size was 2 mL each. Purified proteins were identified by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), combinedand buffer exchanged into
storage buffer. The protein was concentrated to 10-20 mg/mL and stored at -80 °C for further
use.
3.3.6 Lasso peptide precursor peptide purification
After the Trx tag was removed, the protease added two GP residues to the PadeA resulting in a
GP-PadeA peptide. Final purification of GP-PadeA wasthen achieved by two steps HPLC
purification. For this purpose, a preparative HPLC (microbore 1100 HPLC system (Agilent) with
a VP 250/21 Nucleodur C18 Htec 5 μm column (Macherey-Nagel) at room temperature with a
flow rate of 18 mL/min) was used. For the first round, the following gradient of water/0.1%
trifluoroacetic acid (solvent A) and MeCN/0.1% trifluoroacetic acid (solvent B) was used: Linear
increase from 10% to 50% B in 30 min, followed by a linear increase from 50% to 95% B in 2
min and holding 95% B for an additional 3 min. GP-PadeA containing fractions were then
evaporated at 40 °C and reduced pressure. The semipure precursor peptides were then
combined to 10 mL and subsequently applied to a second round of purification using the
following gradient of water/0.1% trifluoroacetic acid (solvent A) and MeCN/0.1% trifluoroacetic
acid (solvent B): Linear increase from 20% to 50% B in 30 min, followed by a linear increase
from 50% to 95% D in 2 min and holding 95% B for additional 3 min. GP-PadeA containing
fractions were collected, confirmed by LC-MS and lyophilized.
3.4 Natural Products Isolation
3.4.1 Extraction of the cell pellets with Methanol
After the fermentation from section 3.3.2, the cell pellets were resuspended with 1 mL ddH2O by
vortex, and then extracted with 60 mL of MeOH for overnight. The mixture was then centrifuged
(6,000 rpm for 20 min at 4 °C) and the pellet were discarded. The extract supernatant was then
filtered and solvent was removed via evaporation at 40 °C and reduced pressure. Dry pellet
extracts were then resuspended in a total of 900 μL of 50% MeOH, cleared by centrifugation
(13,000 rpm for 60 min at 4 °C) and analyzed via LC-MS.
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3.4.2 Extraction of culture supernatants by means of Amberlite XAD 16
On the other hand, culture supernatants were extracted by using XAD16 resin (Sigma Aldrich,
≈7 g/L culture supernatant). The XAD16 containing supernatant was stirred for 1h and was
then removed by filtration. After washed several times with ddH2O, the resin on the filter was
eluted with a total of 60 mL of MeOH. Solvent was then removed via evaporation and reduced
pressure. The dry pelltet were then resuspended in a total of 900 μL of 50% MeOH, cleared by
centrifugation (13,000 rpm for 60 min at 4 °C) and analyzed via LCMS.
3.4.3 Lasso Peptide Purification
Large scale fermentation was performed to isolate the paeninodin and phosphorylated
paeninodin lasso peptide. For each peptide, 10 times 10 L of M9 minimal medium was
fermented at 37 °C for 3 days. Since the ABC transporter is inactive in E. coli, only the pellets
were extracted for lasso peptide. The pellets from 10L fermentation were resuspended by
vortex and extracted with 500 mL of MeOH and the solvent was evaporated at 40 °C and
reduced pressure. Dried extracts were then resuspended in 10 mL of 50% MeOH, cleared by
centrifugation (17000 rpm, 1h). The supernatant was filtered by a Filtropur S filter (0.2 μm) and
were then subjected to preparative HPLC (same as the one used for precursor peptide).
The vector pET41a-PadeCAKB1B2D was used to produce paeninodin in E. coli BL21. For
paeninodin, it was purified by two rounds of HPLC. For the first round, the following gradient of
water/0.045% formic acid (solvent A) and MeOH/0.05% formic acid (solvent B) was used:
Linear increase from 20% to 30% B in 5 min, followed by a linear increase from 30% to 95% B
in 25 min and holding 95% B for an additional 3 min. The pooled fractions of paeninodin were
evaporated at 40°C and reduced pressure. The semipure lasso peptide were combined and
subsequently applied to a second round of purification using the following gradient of
water/0.1% trifluoroacetic acid (solvent A) and MeCN/0.1% trifluoroacetic acid (solvent B):
Linear increase from 10% to 35% B in 30 min, followed by a linear increase from 35% to 95% D
in 2 min and holding 95% B for additional 3 min. The pooled fractions of purepaeninodin were
were collected, confirmed by LC-MS and lyophilized.
The vector PadeCA (ThcoK) B1B2D was used to produce phosphorylated paeninodin in E. coli
BL21. It was also purified by two rounds of HPLC. For the first round, the following gradient of
water/0.045% formic acid (solvent A) and MeOH/0.05% formic acid (solvent B) was used:
Linear increase from 20% to 30% B in 30 min, followed by a linear increase from 30% to 95% B
in 2 min and holding 95% B for an additional 3 min. The pooled fractions of phosphorylated
paeninodin were evaporated at 40°C and reduced pressure. The semipure lasso peptides were
combined and subsequently applied to a second round of purification using the following
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gradient of water/0.1% trifluoroacetic acid (solvent A) and MeCN/0.1% trifluoroacetic acid
(solvent B): Linear increase from 20% to 50% B in 30 min, followed by a linear increase from
50% to 95% D in 2 min and holding 95% B for additional 3 min. The pooled fractions of
purephosphorylated paeninodin were collected, confirmed by LC-MS and lyophilized.
3.5 Analytical Methods
3.5.1 HPLC_MS
Generally, Mass spectrometric analysis of each extracts was performed with a high-resolution
LTQ-FT ultra instrument (Thermo Fisher Scientific) connected to an Agilent 1100 HPLC system
equipped witha detector at 215 nmand with a Nucleosil 300-8 C18 column (125×2 mm,
Macherey and Nagel). The following gradient of water/0.1% trifluoroacetic acid (solvent A) and
MeCN/0.1% trifluoroacetic acid (solvent B) at a column temperature of 40 °C and a flow rate of
0.2 mL/min was applied: holding 2% B for 2 min, followed by a linear increase from 2% to 30%
B in 18 min, a subsequent linear increase from 30% to 95% B in 15 min and holding 95% B for
additional 2 min.
Mass spectrometric analysis was also done with a low-resolution 1100 series MSD (Hewlett-
Packard) coupled with a micropore 1260 HPLC system (Agilent Technologies) for the thermal
stability, protease assays of the purified lasso peptides and all kinds of in vitro assays.
Separations of different compounds were achieved by using different C18 column and specific
gradients. Typically, the following gradient was used at 40 °C column temperature at a flow rate
of 0.3 mL/min: Linear increase from 5% to 30-60 % B in 35 min, followed by a linear increase
from 30-60% to 95% B in 2 min and holding 95% B for additional 5 min.
To quantify each compounds measured, UV-peak areas or intensive of extracted ion
chromatograms was integrated and relative production was determined by comparison between
different samples.
3.5.2 MS-MS fragmentation
In case that we need to further fragment the target mass, collision-induced dissociation
fragmentation studies within the linear ion trap were done using HPLC-MS. Based on the
molecular weight of different compounds, different charged ions were selected for further
fragmentation. Generally, for lasso peptide, [M+2H]2+ ions were selected for fragmentation, as
they were the dominant species in the spectra. For the precursor peptide, the [M+4H]4+ or
[M+5H]5+ were selected for fragmentation, as they were the dominant species in the spectra.
The energy for fragmentation was set to 35%.
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3.5.3 IM-MS spectrometric
For IM-MS analysis of paeninodin, a hybrid quadrupole ion-mobility time-of-flight mass
spectrometer (Waters Synapt G2-Si) equipped with an ESI source operated in positive-ion
mode was employed. Two samples of paeninodin were prepared. One was incubated at 65°C
for 4 h. then mixed with formic acid and the supercharging agent sulfolane. The other was not
heat treated and directly mixed with formic acid and the supercharging agent sulfolane. The
measurements were performed with previously described instrument.
3.5.4 NMR Spectroscopy
For NMR structure determination of paeninodin lasso peptide, paeninodin was dissolved in
different solvents with concentrations varied from 4.5 to 10 mM: H2O/D2O (9:1), CD3OH,
CD3OH/CDCl3 (1:1), CD3OH/CDCl3 (3:1), and DMSO-d6. The temperature dependence was
studied by recording 1H spectra in the range from 278 to 318 K as long as the solvent allowed.
For NMR measurements of modified precursor peptide, 3.3 mg enzymatically generated PadeA
(13-23)-Ser23-OPO32-, 3.2 mg chemically synthesized PadeA (13-23)-Ser23-OPO32-(Biomatik),
and 3.0 mg PadeA (13-23) (Biomatik) were dissolved in 0.2 mL of H2O/D2O (9:1), respectively.
For 1H signal assignment, and NOESYspectra were recorded on a Bruker Avance 600 MHz
spectrometer equipped with an inverse triple resonance 1H-13C-15N probe with z-gradient.
Temperature effect on the spectra was surveyed by recording 1H spectra in a temperature
range from 283 to 308 K. Consequently, all 2D spectra were recorded at 298 K. TOCSY spectra
were recorded with a mixing time of 80 ms, while for NOESY measurements mixing times of
150 and 300 ms were applied. Water suppression was achieved by using excitation sculpting.
The 1D 31P and 2D 1H-31P long-range correlation spectra of the phosphorylated compounds
were recorded on a Bruker Avance III 500 MHz spectrometer with a broadband observation
probe with z-gradient. For the latter, a standard pulse program for HMQC (heteronuclear
multiple quantum correlation) was used, with a gradient ratio of 70:30:80 adjusted to the
observation of 1H-31P correlation and a long-range coupling constant of 7 Hz. 1D 1H spectra
were acquired with 65536 data points, while 2D 1H-1H spectra were collected using 4096 points
in the F2 dimension and 512 increments in the F1 dimension. For 2D spectra, 32 transients
were used, with a relaxation delay of 3.0 s. The 1D 31P spectra were recorded with 12288 scans,
while 2D 1H-31P spectra were recorded with 128 transients and 128 increments in the F1
dimension. Chemical shifts of 1H were referenced to DSS. All spectra were processed with
Bruker TOPSPIN 3.2.
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3.6 Biochemical Methods
3.6.1 Thermal stability studies of Paeninodin and phosphorylated Paeninodin
For the thermostability studies of paeninodinand phosphorylated paeninodin, 10 μg of each
lasso peptide was redissolved in 100 μl ddH2O. The samples were incubated at 20 °C, 35 °C,
50 °C, 65 °C, 80 °C and 95 °C for 4 h, respectivelyand cooled down on ice. The samples and an
untreated sample were then analyzed by LC-MS.
3.6.2 Carboxypeptidase Y assays
To investigate the topology of the paeninodin, a previously established assay in which pure
lasso peptide was heated and then incubated with carboxypeptidase Y was performed112.
10 μg lasso peptide was first heated at 65 °C for 4h and then analyzed by LC-MS, the heat
labile lasso peptide was then readily form two topologies: One is the lasso peptide; one is a
branched cyclic peptide where the tail of the lasso peptide already escaped from the
macrolactam ring. These two compounds have the same mass but a different retention time in
LC-MS. After unthread the lasso peptide, the samples were directly applied into a
carboxypeptidase Y assays. The assays were performed over the course of 4 h at room
temperature. Carboxypeptidase Y assays were done with 0.5 U carboxypeptidase Y per
reaction in a buffer containing 50 mM MES and 1 mM CaCl2 at pH 7.0. After the reaction, the
samples were analyzed via LC-MS.
3.6.3 In vitro phosphorylation assays
Generally, each kind of pure peptide was redissolved in ddH2O to make a 2.5 mM solution
stocks for in vitro studies. A Tris buffer (50 mM Tris •HCl, 5 mM 5 mM MgCl2, 1 ATP and 1 mM
ATP. pH 8.0) was used. The reaction was carried out at 37 °C for 4 h, stopped by the addition of
TFA (final concentration of 5% (v/v)) and subjected to HPLC-MS analysis.
To evaluate the modification position of the phosphate group in the peptide, scale-up
experiments were carried out to synthesize a modified precursor peptide. A truncated version of
the precursor peptide-PadeA (13-23) peptide was used to perform the scale-up assays. The
PadeA(13-23) peptide was chemically synthesized by Biomatik. A typical scale-up assay
mixture (30 mL) contained contained Tris •HCl (50 mM, pH 8.0), MgCl2 (5 mM), ATP (1 mM),
PadeA(13-23) peptide (20 mg, ≈517 µM/L) and recombinant ThcoK ( 2 mg, ≈1.67 µM/L). The
reaction was carried out at 37 °C for 16 h shaking at 220 rpm.
Phosphorylated PadeA (13-23) was then purified by a preparative HPLC (same as the one used
for lasso peptide purification). The following gradient of water/0.1% trifluoroacetic acid (solvent
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A) and MeCN/0.1% trifluoroacetic acid (solvent B) was used: Linear increase from 5% to 25% B
in 30 min, followed by a linear increase from 25% to 95% B in 2 min and holding 95% B for an
additional 5 min. The pooled fractions of phosphorylated PadeA (13-23) were confirmed by LC-
MS, collected and lyophilized. By the scale-up assays, ≈10 mg pure phosphorylated PadeA
(13-23) was isolated as white powder and stored at -20 °C until further usage.
3.6.4 Esterification assays
A chemical modification assays which could selectively methylate all carboxylic acid moieties by
use of methanolic HCl was applied to study the modification position of the peptide132. In a
typically reaction, 10 µg peptide was redissolved in100 µL of 2 M methanolic HCl (prepared by
dropwise addition of 160 µL of acetyl chloride with stirring to 1 mL of cold methanol). The
reaction was performed at 25 °C (500 rpm, 4h). Solvent was then removed by lyophilization and
the resulting sample was redissolved in 100 µL 20% acetonitrile for further HPLC-MS analysis.
Three kinds of peptides were modified in these assays. They are the unmodified PadeA(13-23),
PadeA(13-23)-S23 side chain phosphorylation peptide synthesized by Biomatik and
phosphorylated PadeA(13-23) obtained from scale-up assays.
3.6.5 Antibacterial Assays.
8 different strains were used to investigate the antibacterial activity of paeninodin and
phosphorylated paeninodin by spot-on-lawn assays. They are Bacillus subtilis MR168,
Micrococcus flavus ATCC 10240, Burkholderia rhizoxinica, Sphingobium japonicum,
Xanthomonas citri, Bacillus cereus, Bacillus megaterium WSH-002, and Bacillus
amyloliquefaciens. Soft agar was prepared by adding 0.7% agar to liquid LB. Soft agar (10 mL,
at 48 °C) was then inoculated using 100 µL of an overnight culture of each organism (OD≈
0.01) and spread on an LB agar plate. Then, 10 ng of paeninodin and phosphorylated
paeninodin were spotted on the soft agar plate followed by incubation at 30 °C or 37 °C for 1-3
days.
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4. Results
4.1 Genome Mining for a Novel Lasso Peptide Biosynthetic Gene
Cluster
The number of RiPPs has grown rapidly in recent years40. One reason is due to the large
genome sequencing projects in the past decade. Taking advantage of the available genome
sequence, in silico mining of genomes combined with modern molecular biology has led to the
discovery of a large number of new ribosomal natural products41. This method, called genome
mining, provides a powerful tool to predict and then isolate new lasso peptides. The first
example demonstrated for lasso peptide isolation was Capistruin, which was isolated in 2008127.
Genome mining methods for lasso peptides can generally be divided into two classes. One is
called the precursor-centric genome-mining approach, developed mainly by the A.J. Link group;
the other is called B protein-centric genome mining and has been developed mainly by our
group. Both methods take advantage of sequence homology among genes encoding precursor
peptides or biosynthetic proteins, thus, leading to the identity of new biosynthesis gene clusters.
Since the isolation of Capistruin in 2008, more than 30 different lasso peptides have been
isolated by different genome-mining methods97, 111, 112, 115, 117. Notably, the A.J. Link group
discovered a novel Isopeptidase in 2013 that linearizes lasso peptides, and this proved that the
genome-mining method is also a powerful tool to identify novel enzymes113, 118.
Our group is particularly interested in the B protein-centric genome-mining method because B
protein in lasso peptide biosynthesis gene clusters has a very low homology similarity to other
enzymes. It only has a very low similarity to eukaryotic transglutaminases. Using this method,
our group exploited the lasso peptide biosynthesis world in proteobacteria in depth112. The
discovery of novel lasso peptides included Xanthomonins I-III, a new class of lasso peptides
with a seven-residue macrolactam ring115, Caulonodin lasso peptides with unprecedented N-
terminal residues and several Caulosegninslasso peptides derived from a single biosynthetic
gene cluster111, 116. These lasso peptides broaden the existing knowledge of lasso peptides
greatly and provide diverse scaffolds for further applications. However, lasso peptides have so
far only been isolated from Proteo- and Actinobacterial sources97-99. No other phyla have been
reported that can produce lasso peptide. What is more, lasso peptide biosynthetic gene clusters
typically only encode enzymes for biosynthesis and export; tailoring of lasso peptide is very rare.
Therefore, we here focus on the discovery of novel lasso gene clusters which are different from
the ones already reported.
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4.1.1 Genome Mining Reveals a Novel Lasso Peptide Biosynthetic Gene Cluster
Type in Firmicutes
A B protein-centric genome-mining method was applied to identify a novel lasso peptide
biosynthesis gene cluster. Most of the lasso peptide gene clusters identified have already been
published in our genome-mining paper112. However, interestingly, a family of gene clusters
predominantly found in Firmicutes was identified, which had been overlooked in the past. The
clusters identified contain homologues to the core-conserved genes of known lasso peptide
biosynthetic gene clusters, in addition to a gene coding for a putative kinase (Table 4.1). Other
lasso peptide systems identified also feature a putative sulfotransferase-encoding gene at the
beginning of the biosynthetic operon and/or a putative nucleotidyltransferase-encoding gene
between those coding for the B2 and D homologues129. All the potential lasso peptide gene
clusters identified are summarized in Table 4.1
Table 4.1.Kinase-harboring lasso peptide gene clusters from Firmicutes.
1. Paenibacillusdendritiformis C454 (AHKH01000064.1 23026...28726)
2. Bacillus cereus VD115 (AHFC01000001.1 329527…336459)
3. Bacillus mycoides DSM 2048 (ACMU01000105.1 37016... 43947)
4. Bacillus thuringiensis (NZ_AYPV01000024.1 395713...402624)
5. Bacillus weihenstephanensis (NC_010184.1 3435993... 3442907)
6. Paenibacillusriograndensis (NZ_AGBD01000087.1 30500... 36208)
7. Thermobacilluscomposti KWC4 (NC_019897.1 3352916... 3358626)
8. Paenibacilluspolymyxa (NZ_JWJJ01000002.1 548177...557005)
9. Paenibacillusterrae HPL-003 (NC_016641.1 3033233... 3041545)
10. Paenibacilluspeoriae (NZ_AGFX01000048.1 27851... 35346)
11. Bacillus macauensis (NZ_AKKV01000020.1 16218…23006)
12. Paenibacillusharenae DSM 16969 (NZ_KE383843.1 594303... 599983)
13. Bacillus subterraneus (NZ_JXIQ01000098.1 20476... 27361)
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14. Bacillus kribbensis (NZ_KE387239.1 41261... 48195)
15. Bacillus megateriumWSH-002 (CP003017.1 3899438... 3905391)
16. Bacillus flexus (NZ_JANV01000106.1 11574... 17331)
17. Bacillus oceanisediminis (NZ_ALEG01000067.1 32511... 40721)
18. Bacillus vietnamensis (NZ_CCDN010000009.1 39263... 46139)
19. Bacillus aryabhattai (NZ_JPIE01000001.1 482105... 489018)
20. Paenibacillusalginolyticus (NZ_AUGY01000047.1 37379... 44267)
21. Bacillus endophyticus (NZ_ALIM01000014.1 895870... 901612)
22. Paenibacillusalgorifonticola (NZ_LAQO01000025.1 22190... 29253)
23. Paenibacilluswulumuqiensis (NZ_KQ040793.1 393438... 401239)
24. Paenibacillus borealis (NZ_CP009285.1 998071... 1003776)
25. Bacillus akibai (BAUV01000025.1 34686... 41595)
We selected four typical lasso peptide gene clusters, one each from Paenibacillus dendritiformis
C454, Thermobacillus composti KWC4, Bacillus cereus VD115 and Paenibacillus polymyxa, to
represent the diverse organization of the gene clusters in Firmicutes (Figure 4.1). Surprisingly,
we noticed that even though there are different potential tailoring enzymes associated with the
lasso peptide gene cluster, the precursor peptides among these systems are very similar. All
the lasso peptides predicted bear an N-terminal Ala residue, a feature only recently observed,
similar to Caulonodin lasso peptides116, 129. We hypothesized that these gene clusters originated
from a common ancestor.
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Figure 4.1:(a) Overview of the types of lasso peptide biosynthetic gene clusters identified in Firmicutes. Open
reading frames (ORFs) ending in K, NT and ST encode putative kinases, nucleotidyltransferases and
sulfotransferases, respectively. (b) Alignment of the corresponding precursor peptides
We then performed a blast analysis of potential tailoring enzymes surrounding the lasso peptide
gene cluster. They indeed show some homology to known enzymes. Table 4.2 provides an
overview of these genes, their putative roles and arrangements within the clusters
Table 4.2.Proposed functions of the ORFs in the putative lasso peptide biosynthetic gene clusters that were identified
by genome mining in Firmicutes.
Protein length(aa) GenBank accessionno. proposed function conserved domain analysis
PadeA
ThcoA
BaceA
PapoA
42
42
41
42
-
AGA59244.1
EJR65203.1
YP_008910696.1
precursor peptides -
PadeB1
ThcoB1
BaceB1
PapoB1
99
98
101
100
WP_006678398.1
AGA59242.1
EJR65205.1
YP_008910698.1
maturation enzymes,
B1part of ‘split B’,
protease
PqqD superfamily,
coenzyme PQQ synthesis protein
D
PadeB2
ThcoB2
BaceB2
PapoB2
142
163
157
161
WP_006678399.1
AGA59241.1
EJR65206.1
YP_008910699.1
maturation enzymes,
B2part of ‘split B’,
protease
transglutaminase-like superfamily
PadeC
ThcoC
BaceC
PapoC
649
645
645
641
WP_006678396.1
AGA59245.1
EJR65202.1
YP_008910695.1
maturation enzymes,
adenylation,
cyclization
glutamine amidotransferases class-
II (GATase) asparagine synthase_B
type
PadeD
ThcoD
BaceD
PapoD
607
607
599
601
WP_006678400.1
AGA59240.1
EJR65208.1
YP_008910701.1
export,
immunity protein
ABC-type multidrug transport
system
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PadeK
ThcoK
BaceK
PapoK
313
310
328
351
WP_006678397.1
AGA59243.1
EJR65204.1
YP_008910697.1
putative kinase HPrK-related kinase,
BaceNT
PapoNT
400
506
EJR65207.1
YP_008910700.1
putative
nucleotidyltransferase
uncharacterized
nucleotidyltransferase
PapoST 422 YP_008910694.1 putative pulfotransferase sulfotransferase family
4.1.2 Genome Mining Reveals a Novel Lasso Peptide Biosynthetic Gene Cluster
Type in Proteobacteria
After we identified the lasso peptide gene clusters in Firmicutes which had been overlooked and
considering the rare organization of the gene cluster, we thought that there are group a of novel
and cryptic lasso peptide gene clusters which have overlooked in the past. Therefore, we used
the kinase from Firmicutes to further exploit the lasso peptide biosynthesis diversity by a kinase
homology-based genome-mining method. This could give us a chance to perform a global
survey of lasso peptide gene clusters featuring at least one tailoring enzyme. We found that
these kinase homologues exist widely in nature. We could also identify several clusters from
Proteobacteria preferring an AB1B2CKD organization, which was predicted in our B protein-
centric genome-mining paper112 (Table 4.3). All the B homologues in these clusters are split into
B1 and B2. Remarkably, all the kinase-featured lasso peptide gene clusters from Proteobacteria
are generally lacking in the nucleotidyltransferase and sulfotransferase found in Firmicutes.
Several potential lasso peptide gene clusters from Proteobacteria are summarized in Table 4.3.
Table 4.3.Kinase-harboring lasso peptide gene clusters from Proteobacteria.
26. Sphingobiumyanoikuyae (AGZU01000016.1 543969... 549488)
27. Mesorhizobium loti (NZ_KB913026.1 6199725... 6205323)
28. Mesorhizobiumopportunistum (CP002279.1 267289... 273124)
29. Mesorhizobiumciceri(NZ_AWZS01000002.1 71030... 76676)
30. Mesorhizobiumamorphae (AGSN01000187.1 19062... 24852)
31. Mesorhizobiumaustralicum (NC_019973.1 265394... 271267)
32. Rhodobactersphaeroides(CP001150.1 875732.... 881323)
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33. Sphingomonassp. Y57 (NZ_LDES01000074.1 26756... 32158)
34. Mesorhizobium sp. WSM1293 (NZ_KI911320.1 331530... 337146)
35. Altererythrobacteratlanticus (NZ_CP011452.1 1803258... 1808418)
4.1.3 Phylogenetic tree of the 35 kinase-containing lasso peptide biosynthetic
gene clusters identified
We then performed a phylogenetic analysis of the kinase and its homologies. The kinase
sequences were retrieved from the gene clusters and phylogenetic trees were constructed
using the minimum evolution and neighbor-joining method. Phylogenetic trees derived from all
these 35 kinases clearly segregate into two clades (as shown in Fig. 4.2), even though it seems
that these two different subfamilies are close to each other and probably originated from the
same ancestor. The lasso peptide gene clusters from Firmicutes generally prefer an
XCAKB1B2XD organization, while clusters from Proteobacteria prefer an AB1B2CKD
organization. All the B homologues in these clusters are split into B1 and B2. Remarkably, 16
out of 25 gene clusters from Firmicutes also featured an uncharacterized nucleotidyltransferase.
Two gene clusters featured a sulfotransferase, making the gene cluster more diverse. These
transferases are highly likely to be novel tailoring enzymes for the lasso peptide, but, at the
present time, the functions of these enzymes are still elusive. Further investigations are, thus,
needed129.
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Figure4.2:Phylogenetic tree of the 35 kinase-containing lasso peptide biosynthetic gene clusters identified.
4.1.4 Comparison of precursor peptides from kinase-harboring lasso peptide
biosynthetic gene clusters
The precursor peptide or the mature lasso peptide could be the substrate of the kinase. We
subsequently turned our attention to the precursor peptide. We first identified the precursor
gene manually in order to compare the precursor peptides. The precursors were generally
predicated based on three conserved features of lasso peptide precursors: 1) a Thr residue at
the penultimate position of the leader peptide, 2) N-terminal glycine, cysteine, serinine or
alanine on mature lasso peptide and 3) aspartate or glutamate being the last residue in the ring
at position 7, 8 or 9. After we had identified all the precursor peptides, the precursor peptide
sequences were retrieved from the gene clusters and alignment was performed. Overall, the
RESULTS
62
precursors are highly conserved in their own clades (Figure 4.3). Regarding the precursors from
Firmicutes, the core peptide prefers starting with an alanine, while the core peptide from
Proteobacteria prefers starting with a glycine. However, they both like forming a nine-residue
macrolactam ring with an aspartic acid. The Thr residue in the penultimate position of the leader
peptide is also conserved in both clades. Precursors from Firmicutes are generally polar,
negatively charged with lots of aspartic or glutamic acid residues in both the leader peptide and
core peptide region, while precursors from Proteobacteria are mostly hydrophobic in the core
peptide region and polar in the leader peptide region. We then chose one precursor from each
clade and did an alignment. There is no similarity between these two precursors except the last
serine (Figure 4.3).
This suggested that these gene clusters indeed segregate into two clades and we hypothesized
that these kinases specifically recognize the last serine of the precursor peptide and have a
wide substrate specificity129.
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Figure4.3:Multiple sequence alignment of precursor peptides from kinase-harboring lasso peptide biosynthetic gene
clusters. Alignment of the precursor peptides found in (A) Firmicutes and (B) Proteobacteria. (C) Comparison of
precursor peptides from Firmicutes and Proteobacteria to each other.
4.2 Discovery and Isolation of Lasso Peptide Paeninodin and
Phosphorylated Paeninodin
After we had identified these novel lasso peptide gene clusters, we turned our attention to look
for the natural products. We chose the putative lasso peptide biosynthetic gene cluster from P.
dendritiformis C454 as a target for further investigation. This gene cluster contains the
additional kinase-encoding gene (padeK) compared to previously characterized systems.
Moreover, it is the first lasso gene cluster investigated from Firmicutes129.
We first worked on the wild strain of P. dendritiformis C454 to see if the native strain could
produce the lasso peptide. For this purpose, P. dendritiformis C454 was fermented in various
medium, such as M9, LB andCASO medium. The pellets and supernatant of each fermentation
were extracted and analyzed by mass spectrometry. To our surprise, the fermentation extracts
of native P. dendritiformis C454 failed to produce any lasso peptide. A heterologous approach
had to be developed to solve this problem.
4.2.1 Heterologous production of the novel lasso peptide paeninodin and
phosphorylated paeninodin in E. coli
It was found from the studies of the lasso peptide capistruin that lasso peptide gene clusters
from Proteobacteria could be heterologously expressed in E. coli112, 127. Since then, more than
20 lasso peptides from Proteobacteria have been produced in this way97. For our studies, the
gene cluster is from Firmicutes and a similar approach has been adopted, but the risk is very
high. We used our previous method and the cluster was cloned into the pET41a, which is under
the control of the T7 promoter. We then expressed these constructs and the empty pET41a
vector as a control in E. coli BL21. An amount of 600 ml M9 minimal medium was chosen for
the initial screens under 1, 2 and 3 days at 37 °C and 3 days at 20 °C.
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Figure4.4:Comparison of relative lasso peptide production for the different fermentation conditions. 3D20, 3 days at
20 °C; 1D37, 1 day at 37 °C; 2D37, 2 days at 37 °C; and 1D37, 3 days at 37 °C.
We then harvested the cultures, threw away the supernatants and extracted the cell pellets with
50 mL MeOH overnight. Next, solvent was removed via evaporation at 40 °C and reduced
pressure. The dry pellet was then resuspended in a total of 900 μL 50 % MeOH, and cleared by
centrifugation (13000 rpm, 1 h). Subsequently, the supernatant was analyzed by HPLC-MS.
Results showed that under three days at 37 °C was the best condition for the production (Figure
4.4) and comparison with an empty vector control confirmed the presence of two additional
major peaks ([M+2H]2+ observed = 1200.5023, retention time = 21 min; [M+2H]2+ observed =
1240.4796. retention time = 20 min) in the pET41a-CAKB1B2D constructs (Figure 4.5). These
two UV peaks indicated that there truly was a modification happening to the wild lasso peptide.
The first hypothesis was that this unknown kinase endows the lasso peptide with a phosphate
group, and we named this novel lasso peptide paeninodin and phosphorylated paeninodin129.
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Figure4.5: (a) Vector map of the heterologous paeninodin production plasmid. (b) UV traces of the LC-MS analyses
of pellet extracts of cultures after expression of an empty vector control, the complete cluster in pET41a, respectively.
4.2.2 Mass spectrometric analysis
In order to acquire additional information, especially of the modification position of the lasso
peptide, extensive mass spectrometric studies on both paeninodin and phosphorylated
paeninodin were carried out on a LTQ-FT instrument by collision-induced dissociation (CID).
The MS2 fragmentation gives a clear y and b series of fragment ions of the lasso peptide, as
shown in Figure 4.6. The smallest b fragment (b10) and the largest y series fragment (y14) of
paeninodin and phosphorylated paeninodin observed correspond to the ring plus alanine and
the tail, respectively. This proves that the internal backbone to side chain cyclization is between
residue Ala1 and Asp9. Comparing the MS2 fragmentation of unmodified and modified lasso
peptide, the main difference is the y series, and the difference between each series is about 80.
This indicates that the modification happens at the tail of the lasso peptide and the tailoring
enzyme could phosphorylate the lasso peptide. Furthermore, the smallest y series fragment (y4)
from the paeninodin observed proves that the modification happens at the last four residues of
the peptide. To further confirm the modification position of the phosphate group, we selected the
y11 fragment of both paeninodin and phosphorylated paeninodin and carried out a further MS3
fragmentation experiment. The MS3 fragmentation spectra show the characteristic
fragmentation pattern of each peptide clearly. Comparing these two spectra, the b series
fragment (b11) observed plus a phosphate group demonstrates clearly that the phosphate
group is attached at the last serine residue129.
In conclusion, the mass spectrometric results suggest the peptide is a lasso peptide with a
phosphate group at the last serine residue. However, since the serine has a hydroxyl group at
the side chain and a carboxyl group at the C-terminus, it is unclear at which position the
modification happens. Thus, further experiments are necessary to prove it.
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Figure4.6:MS2 spectra of (a) paeninodin and (c) paeninodin-OPO32-, and MS3 spectra of the y11 fragments of (b)
paeninodin and (d) paeninodin-OPO32-.
4.2.3The kinase is responsible for the modification of paeninodin
We hypothesized that this unknown kinase endows the lasso peptide with a phosphate group.
To confirm this hypothesis, the kinase gene was knocked out by SLIM mutagenesis. The
resulting plasmid was named pET41a-PadeCAB1B2D and transferred into E. coli BL21.
Meanwhile, the plasmid pACYCDuet-1-PadeK was used to complement E. coli BL21 harboring
pET41a-PadeCAB1B2D. By using the same procedure, extracts from these cultures were
analyzed for the presence of paeninodin. Whereas the strain harboring pET41a-
PadeCAKB1B2D could produce both paeninodin and phosphorylated paeninodin, no
phosphorylated paeninodin could be detected in the extract from strains harboring pET41a-
PadeCAB1B2D, as shown in Figure 4.7. On the other hand, after the plasmid pACYDuet-1-
PadeK, which encodes the unknown kinase, was used to complement E. coli BL21 harboring
pET41a-PadeCAB1B2D, the HPLC-MS experiments demonstrated clearly that phosphorylated
paeninodin production was restored upon complementation, even though the overall yield
decreased (Figure 4.7B). Altogether, these data showed that this kinase is responsible for the
modification of lasso peptide, hence, we were able to identify a novel lasso peptide tailoring
enzyme for the first time129.
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Figure4.7:(a) Vector map of the heterologous paeninodin production plasmid. (b) UV traces of the LC-MS analyses
of pellet extracts of cultures after expression of an empty vector control, the complete cluster in pET41a, the padeK
knock-out cluster and the supplementation of the knock-out plasmid with padeKpACYC, respectively.
4.3 Characterization of Lasso Peptide Paeninodin and Phosphorylated
Paeninodin
4.3.1 Purification of paeninodin and paeninodin-OPO3-2
After we had initially observed that cultivation in M20 medium at 37 °C for three days is the best
heterologous condition for the production of paeninodin and its analog, we tried to engineer the
biosynthetic pathway to increase the yield. We use our past method to incorporate an artificial
ribosomal binding site between genes and tried to rearrange the order of the genes112. However,
none of them would work (data not shown). On the basis of these facts, we used this condition
and performed large-scale fermentations to isolate our lasso peptides. The culture was scaled-
up to 100 L volume in order to obtain sufficient amounts of lasso peptide for NMR structure
elucidation studies and other assays. The cell pellets of the fermentation were extracted with
MeOH and the solvent was evaporated at 40 °C and reduced pressure. The dry pellet was then
resuspended in 50 % MeOH and cleared by centrifugation (17000 rpm, 1 h). Subsequently, the
supernatant was used to purify the lasso peptide. Purification of a large amount was achieved
by preparative HPLC (See methods; Figures 4.8 and 4.9). At the end, paeninodin could be
purified with a yield of 0.1 mg/L culture, while phosphorylated paedenin could be purified with a
yield of 0.05 mg/L culture. The unmodified and modified lasso peptide is enough for further
studies129.
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Figure4.8:Chromatograms of the paeninodin purification by preparative HPLC. (A) First purification with
water/0.05 % formic acid and MeOH/0.045 % formic acid. (B) Second purification with water/0.1 % TFA and
MeCN/0.1 % TFA.
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Figure4.9: Chromatograms of the paeninodin-OPO32-purification by preparative HPLC. (A) First purification with
water/0.05 % formic acid and MeOH/0.045 % formic acid. (B) Second purification with water/0.1 % TFA and
MeCN/0.1 % TFA.
4.3.2 Confirmation of the lasso topology of paeninodin
4.3.2.1 Thermal stability
After producing paeninodin and phosphorylated paeninodin, we first wanted to test the thermal
stability of the lasso peptide and especially the thermal stability of the modified lasso peptide.
Normally, neither a phosphate ester nor a mixed carbonic-phosphoric anhydride is chemically
stable in aqueous solution at physiological pH. Since the modified lasso peptide is only 20 % of
the wild type, it is unclear whether this is due to the hydrolysis of itself or the kinase activity is
just low. A solution of 10 μg of purified paeninodin and phosphorylated paeninodin were
incubated at 20, 35, 50, 65, 80 and 95 °C for 4 h, respectively, to study the thermal stability.
Samples were then cooled on ice and were, subsequently, analyzed via LC-MS using
appropriate gradients. The paeninodin lasso peptide turns out to be a moderate thermostable
lasso peptide (Figure 6A). It showed only minimal unthreading after 4 h at 50 °C, while under
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65 °C for 4 h, not only does the lasso peptide start unthreading, it also tends to decompose,
resulting in two main degradation products. One is the nine-amino acid macrolactam ring plus
five amino acids and the nine-amino acids tail peptide129. This phenomenon was also observed
in the thermal stability studies of caulosegnin lasso peptide111. The aspartate residue located
between these two proline amino acids seems be able to catalyze the self-hydrolysis of the
lasso peptide via formation of a cyclic imide intermediate, which proves the lasso peptide not a
thermostable lasso peptide. The stability profile of phosphorylated paeninodin is similar to the
wild type lasso peptide, but, surprisingly, the modification is quite stable and is still attached at
the nine-amino acids tail peptide even after 4 h at 95 °C (Figure 4.10). This actually gives us a
hint that the activity of the kinase in this gene cluster is just very low and in vitro studies might
prove our hypothesis.
Figure4.10:(a) UV traces of LC-MS analyses of paeninodin samples after incubation for 4 h at different temperatures.
(b) UV traces of LC-MS analyses of paeninodin-OPO32-samples after incubation for 4 h at different temperatures.
4.3.2.2 Proteolytic stability
Several strategies have been developed to distinguish the topology of lasso peptide in the past.
Firstly, carboxypeptidase Y assays were performed to prove that the paeninodin is a true lasso
peptide. This method has been widely applied to investigate the topology of lasso peptide in the
past111, 112, 115. The carboxypeptidase Y can normally cleave off amino acids from the C-terminus
of a peptide chain. We observed in the heat stability assays that the paeninodin is a heat-labile
lasso peptide. The paeninodin forms two topologies readily at 65 °C for 4 h. One is the lasso
fold and the other is a branched cyclic peptide. Theoretically, the carboxypeptidase Y could only
degrade the tail of the lasso peptide that is not shielded by the surrounding macrolactam ring,
while the carboxypeptidase Y could further degrade the branched cyclic peptide’s tail. The
branched cyclic analog of paeninodin was digested until only one additional amino acid after the
macrolactam ring was present, as shown in Figure 4.11, thus, proving the topology proposed.
By contrast, there is no degradation of the lasso peptide which proves that it has a lasso fold
and the macrolactam ring is able to sterically shield amino acids positioned inside or close by
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the ring. Moreover, this is also a hint that the lasso peptide has a very short tail, which is
another proof that the H20 and Y21 act as the plug amino acids on opposite sides of the
macrolactam129.
Figure4.11:Result of the carboxypeptidase Y treatment of paeninodin after prior incubation for 4 h at 65 °C.
4.3.2.3 IM-MS
IM-MS analysis of paeninodin was carried out to further substantiate these findings (Figure
4.12). IM-MS analysis of (a) untreated paeninodin and (b) a sample of paeninodin after
incubation for 4 h at 65 °C gave two different results, as is shown in Figure 4.12. The peaks of
the [M+4H]4+ ions corresponding to paeninodin and its branched-cyclic analog are also shown in
Figure 4.12129 (theoretical value = 600.7534). It can be clearly seen that a new peak with a
longer drift time (and, therefore, belonging to a compound with a larger collision cross-section)
appears next to the double peak of the lasso peptide after thermal treatment of paeninodin,
which is in accordance with previous IM-MS studies on lasso peptides and their branched-cyclic
analogs133. This result provides further evidence that the new compound, sharing the lasso
peptide’s mass and observed after incubation at 65 °C, is a branched-cyclic peptide resulting
from thermally-induced unthreading of paeninodin. The observation of a double peak for the
lasso peptide suggests that paeninodin can adopt multiple, distinct and interchangeable
conformations in its native state129.
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Figure4.12: IM-MS analysis of (a) untreated paeninodin and (b) a sample of paeninodin after incubation for 4 h at
65 °C. The peaks of the [M+4H]4+ ions corresponding to paeninodin and its branched-cyclic analog (theoretical value
= 600.7534) are shown.
4.3.2.4 NMR studies and structure elucidation
Efforts were taken to determine the three-dimensional structure of paeninodin. Firstly, a solution
of paeninodin in water (~40 mg/mL) was subjected to sparse-matrix screening (Qiagen). As no
crystal growth was observed even after 50 days, structure elucidation was attempted via NMR
spectroscopy129. For this, purified paeninodin was dissolved in five solution variants containing
four different solvents: H2O/D2O (9:1), CD3OH, CD3OH/CDCl3 (1:1), CD3OH/CDCl3 (3:1) and
DMSO-d6. The lasso peptide concentration was varied from 4.5 to 10.0 mM, while temperature
dependence was studied by recording 1H spectra in the range of 278 to 318 K. To our surprise,
the 1H spectra obtained (Figure 4.13) showed resonance signals in the amide proton region
(6.5 – 9.5 ppm), corresponding to more than one set of paeninodin structures (the primary
sequence contains 19 NH) at reduced temperature in all systems tested. Changes in signal line
width and number in this region were observed at higher temperatures, and are assumed to be
due to chemical exchange in solution129. At first, we suspected sample degradation (e.g.
unthreading or breaking of the Asp14-Pro15 bond, as shown in Figure 4.10) under the
experimental conditions; however, LC-MS analysis, carried out on samples following NMR
measurements, discounted this. Therefore, we hypothesize that paeninodin may adopt more
than one stable conformation in solution. In addition, we propose that these coexisting
conformations undergo rapid chemical exchange, which results in overlapping signals and
hinders NMR structure determination. A few natural peptides were shown to assume multiple,
stable and distinct conformations; in these cases, NMR structure solution was possible, albeit
challenging. As the thermal instability of paeninodin prevented the recording of NMR spectra at
higher temperatures, structure determination was impossible for this lasso peptide129.
Nevertheless, in accordance with numerous previous publications111,112, a series of analytical
assays already show that paeninodin exhibits the typical characteristics of a lasso peptide.
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Figure4.13:1H-NMR spectra of amide protonsin in the 6-11 ppm region of paeninodin, collected at various
temperatures in (a)H2O/D2O (9:1), (b)CD3OH, (c)CD3 OH/CDCl3 (1:1) and (d)DMSO-d6.
4.3.3 Antibacterial Assays
Paeninodin is a lasso peptide originating from a gene cluster featuring an ABC transporter. Past
research has shown that only Mccj25, capistruin, lariatin and streptomonomicin, which have an
associated ABC transporter, are antimicrobial peptides105, 125, 127. This makes sense, since the
ABC transporter serves as an exporter, immunity factor and self-protective mechanism. On the
basis of that, paeninodin is a potential antimicrobial peptide. The antibacterial activities of
paeninodin and phosphorylated paeninodin were evaluated by spot-on-lawn assays against
Bacillus subtilis MR168, Micrococcus flavus ATCC 10240, Burkholderia rhizoxinica,
Sphingobium japonicum, Xanthomonas citri, Bacillus cereus, Bacillus megaterium WSH-002
and Bacillus amyloliquefaciens. All the antibacterial assays turned out to be negative. This is
probably due to a lack of high-throughput screening tools in our lab or these lasso peptides
serve as signal molecules129. Further screening for the antimicrobial activity of paeninodin and
phosphorylated paeninodin is on the way.
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4.4 Mutagenesis of the Paeninodin Gene Cluster
Because paeninodin could be synthesized heterologously in E. coli, a mutational analysis of the
PadeA gene in vivo was performed to gain first insights into the biosynthesis and modification
position of this lasso peptide. This approach has been extensively applied to study microcin J25,
capistruin and other lasso peptides discovered recently to gain insights into their biosynthesis or
engineering111, 114-116, 134. Based on past experiences, a total of 14 mutants were generated
based on carefully selected key residues in the precursor (Figure 4.14).
Figure4.14:Mutational analysis of padeA and its effect on paeninodin production levels. A production level of 100 %
refers to the sum of modified and unmodified paeninodin observed for the wild type system. A schematic of the
proposed primary structure of paeninodin is shown above.
Past research has shown that the conserved Thr residue in the penultimate position of the
leader peptide of lasso peptides is a recognition element for the lasso peptide maturation
machinery126. Our mutational analysis shows that the processing enzymes of the paedenin
biosynthetic gene cluster tolerate substitutions of the Thr residue at the penultimate position of
the leader peptide, but the yield of the lasso peptide production is indeed affected. The T-2A
variant produced only 31 % of the wild type, while T-2V produced 33 % of the wild type. In
agreement with the studies for caulosegnins lasso peptides, the best tolerated substitution was
T-2C, showing a production that was about 50 % of the wild type. On the other hand, all these
mutations did not affect the ratios of the modified and unmodified lasso peptide129.
Paedenin is another rare example of lasso peptide starting with alanine. Although caulonodin
and streptomonomicin, recent newly isolated lasso peptides, demonstrate that lasso peptide
could feature a serine or alanine at position 1 of the core peptide, no lasso peptide with an Ala-
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Asp isopeptide linkage has been reported yet105, 116. Before these two examples, the first
residue of all lasso peptides reported was limited to Gly or Cys. In accordance with other
mutational studies of caulonodin, which is the first example of lasso peptides featuring a serine
or alanine residue at the N-terminus, the tolerance for substitution at this position of paedenin
was very limited116. The A1C mutations abolished the production completely, while, in the cases
of A1G and A1S mutations, at least trace amounts of the lasso peptides predicted were still
detectable. It is worth noting that in our genome-mining survey, we noticed that most of the
potential lasso peptide in bacilli prefers starting with an alanine, indicating that this is a key
residue specifically recognized by the processing enzymes of this class of lasso peptide.
Considering the highly conserved sequence of the precursor in bacilli, these lasso peptide gene
clusters are probably originally from the same ancestor. The D8E variant was also not produced,
suggesting that the macrolactam ring size is also important for enzymatic recognition129.
We then turned our attention to the tail to get further information about the so-called plug amino
acids for maintenance of the lasso fold. Since paeninodin is a nine-ring lasso peptide, the
residue needed to trap the tail must be rather large, such as aromatic amino acids. It is possible
to get hints by mutagenesis about which amino acid actually served as a plug. Hence, a set of
mutants focusing on the last four amino acids was created in vivo. The alanine scan of the last
four amino acids indicated that Y21 is probably responsible for the entrapment of the tail, since
only this mutation Y21A abolished the production completely. Meanwhile, the mutation H20A
was only produced at 11 % of the wild type. On the other hand, the Y21F, D22A and S23A
variants are produced at a level more or less the same as the wild type129. We guess that the
H20 and Y21 act as the plug amino acids on opposite sides of the ring, forming a sandwich-like
structure, as it is the case with microcin J25125.
Another advantage of these mutational studies is that we could have a first glance at the
substrate specificity of the kinase. The kinase could modify the H20A, Y21F and D22A variants,
indicating it could tolerate substitutions of this region. Moreover, we already know from the
mass spectrometric results that the phosphate group is at the last serine residue, but we do not
know whether it is at the side chain hydroxyl group or at the carboxyl group at the C-terminus.
Mutational studies could give us a first clue. All the mutations at the S23 position could produce
unmodified lasso peptide at the same level as the wild type, but no modified lasso peptide
variants could be observed on the UV level. These mutations almost abolished the production of
the modified lasso peptide; it is also highly likely that the modification happens at the side chain
hydroxyl group of the serine129. However, further experiments are still needed to prove the
modification position.
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4.5 Modification Pathway
4.5.1 Recombinant production and purification of active PadeK kinase
After purifying paeninodin and phosphorylated paeninodin and figuring out their topology, we
come to the question, how does the modification happen? Due to the unusual knot structure of
lasso peptide, the first hypothesis is that lasso peptide is, firstly, synthesized by the mature
enzymes and then modified by the kinase to yield the final products. In fact, a new protease-
AtxE2 has recently been shown to be a novel lasso peptide isopeptidase that hydrolyzes
astexins-2 and -3 specifically and converts them to linear peptides113. This enzyme works by
recognizing the lasso topology rather than a specific amino acid sequence. Inspired by this
example, we first investigated whether this enzyme had any activity toward paeninodin lasso
peptide.
Consequently, an in vitro study was required. Unfortunately, initial attempts to get soluble
PadeK kinase failed. Therefore, a Maltose-binding protein (MBP)-fusion tag was used to
facilitate the purification (Figure 4.15). The gene was cloned into pETMBP_1a vector and
introduced into E. coli BL21 (DE3) cells for protein overproduction (Figure 4.15).
RESULTS
77
Figure4.15:Methods for the production of PadeK. A Maltose-binding protein (MBP)-fusion tag (with N-terminal His6-
tag) was used to facilitate purification. An HRV-3C protease site was introduced between the MBP-fusion tag and
PadeK.
The MBP-PadeK was then purified by a Ni-NTA column and treated with Hrv-3C protease for
tag removal. PadeK is notably difficult to handle, because it tends to form aggregates with itself
and MBP129 (Figure 4.16).
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Figure4.16: (A) SDS-PAGE gel of purified MBP-PadeK (lane 2, 67 kDa) and protein marker (lane 1). (B) SDS-PAGE
gel of purified PadeK (lane 2, 32 kDa) and protein marker (lane 1).
4.5.2 Recombinant production and purification of GP-PadeA precursor peptide
We hypothesized that the kinase, firstly, modifies the precursor to form modified precursor, then
the mature enzymes transfer the modified precursor into the final lasso peptide. To prove this
hypothesis, the precursor peptide PadeA should be produced first. The precursor peptide is
hard to synthesize by chemical methods, therefore, we produced the PadeA via a heterologous
expression method88. The PadeA gene was, firstly, amplified from the chromosomal DNA of P.
dendritiformis C454. The Pade A gene was then cloned into a pET-48b(+) vector, resulting in a
pET-48b(+)-PadeA vector (Figure 4.17). In this way, the PadeA is fused with a thioredoxin gene,
which is connected by the sequence of the Hrv-3C protease cleavage site. Subsequently, E. coli
BL21 (DE3) cells were transformed with the resulting pET-48b(+)-PadeA plasmid. The
subsequent expression of the thioredoxin PadeA fusion protein was carried out in LB medium.
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Figure4.17:Methods for the production of GP-PadeA and its variants. A Trx-fusion tag was used to facilitate
purification. An HRV-3C protease site was introduced between the Trx-fusion tag and PadeA. After proteolytic
cleavage, GP residues remained on the N-terminus of the PadeA precursor peptide. The identity of the resulting GP-
PadeA was confirmed by MS.
After purification by Ni-NTA, the fusion protein was cleaved by digestion with the Hrv-3C
protease. As a result of a final purification by HPLC, a PadeA derivative with two additional
glycine and proline residues at the N-terminus (GP-PadeA) could be obtained129 (see Figure
4.18).
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Figure4.18:Chromatograms of the GP-PadeA purification by preparative HPLC. (A) First purification with water/0.1 %
TFA and MeCN/0.1 % TFA. (B) Second purification with water/0.1 % TFA and MeCN/0.1 % TFA and a different
gradient.
The base sequence of pET-48b(+)-PadeA plasmid was mutated using the SLIM method for the
synthesis of GP-PadeA variants. Subsequently, the newly obtained pET-48b (+) PadeA variant
vectors were transformed into E. coli BL21 (DE3) cells. The respective thioredoxin PadeA
variants fusion protein was expressed in LB medium purified by Ni2+-NTA affinity
chromatography and cleaved using the Hrv3C protease. The final purification of the precursor
peptide variants was achieved by preparative HPLC129.
4.5.3 Recombinant production and purification of active ThcoK kinase
Due to difficulties isolating PadeK, we searched our genome-mining results for a suitable
homologue. We found that a kinase from the cluster of T. composti KWC4 (ThcoK) could be a
good candidate. The high degree of sequence similarity of precursor peptides padeA and thcoA
(~ 64 % identity) and associated kinases (~ 41 % identity; ~ 58 % similarity) was expected to
facilitate homologous exchange129.
The ThcoK gene was amplified directly from the chromosomal DNA of T. composti KWC4. The
ThcoK gene was then cloned into a pET-41a(+) vector, resulting in a pET-41-ThcoK vector.
ThcoK was then purified by a Ni-NTA column and size exclusion chromatography (Figure 4.19).
It was notable that even though the ThcoK is super soluble, it tends to form aggregates with
itself when the temperature is changed drastically. We handled this enzyme consistently at
room temperature129.
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Figure4.19:(A) Map of the pET41a-thcoK plasmid used for the expression of His-tagged ThcoK. (B) SDS-PAGE gel
of purified ThcoK (lane 2, 35 kDa) and protein marker (lane 1).
4.5.4 Exchange of the ThcoK kinase into the paeninodin biosynthesis gene
cluster
After we had demonstrated that ThcoK is a more soluble enzyme and easier to handle, we
needed to further prove that ThcoK is suitable for homologous exchange. In order to prove that
Thcok is able to modify the paeninodin lasso peptide, we exchanged the ThcoK kinase into the
paeninodin biosynthesis gene cluster by SLIM mutagenesis. We replaced the PadeK directly
with this kinase (ThcoK) in the pET41a-PadeCAKB1B2D vector, resulting a new construct
called pET41a-PadeCA(ThcoK)B1B2D and transformed it into an E. coli BL21(DE3) cell. New
fermentation was performed and, by using the same procedure, extracts from these cultures
were analyzed for the presence of phosphorylated paeninodin (Figure 4.20). By incorporating
with this kinase, we noticed surprisingly that the modified lasso peptide is now the major product
in the extract (≈ 80 %). This demonstrated that the kinase in the lasso peptide gene clusters is
changeable129.
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Figure4.20:HPLC analysis and extracted ion chromatograms of pellet extracts from pET41a-padeCAKB1B2D and
pET41a-padeCA-thcoK-padeB1B2D fermentations.
4.5.5 The kinase only modifies the precursor peptide, not the mature lasso
peptide
After we had obtained two soluble kinases (PadeK and ThcoK) and two potential substrates
(PadeA and paeninodin), we came to the question, how does the modification happen? Due to
the unusual knot structure of lasso peptide, the first hypothesis is that lasso peptide is firstly
synthesized by the mature enzymes and then modified by the kinase to yield the final products.
We, initially, investigated whether this enzyme had any activity toward paedenin lasso peptide.
Firstly, PadeK was employed in an in vitro assay using paedenin as a substrate.A standard
reaction (50 μL) in vitro generally contained Tris ·HCl (50 mM, pH 8.0), MgCl2 (5 mM), ATP (1
mM), substrate (50 μM) and enzyme (5 μM). Surprisingly, no activity was observed. This led us
to think of the second hypothesis, that the kinase initially modified the precursor to form
modified precursor, then the mature enzymes transferred the modified precursor into the final
lasso peptide. To prove this hypothesis, another in vitro assay using GP-PadeA was performed.
This time, trace amounts of the modified precursor predicted were detected129 (Figure 4.21).
RESULTS
83
Figure4.21:Extracted ion chromatograms and mass spectra of GP-PadeA and GP-PadeA-OPO32- from the assay
with PadeK.
We then directly performed mass spectrometric analysis of the products. MS2 fragmentation
and further MS3 fragmentation of the y-11 fragment confirmed that the kinase could actually
modify the precursor peptide (Figure 4.22). However, due to the low solubility of the kinase, the
activity of the enzyme is very low, which hinders our further studies of the kinase. This could
also explain why the modified lasso peptide is only 20 % of the unmodified lasso peptide in the
cell extract.
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Figure4.22:MS2 spectra of GP-PadeA and GP-PadeA-OPO32-. The latter resulted from the assay of PadeK and GP-
PadeA.
As shown before, we demonstrated that the kinase in the lasso peptide gene clusters is
changeable. Since ThcoK kinase could also effectively modify the peadenin lasso peptide, we
then focused on this kinase and repeated the assays. Therefore, another in vitro assay using
GP-PadeA and ThcoK was performed in the standard assay. As expected, the ThcoK could
effectively transform the precursor into modified precursor with a yield of about 80 % (Figure
4.23). Further MS analysis confirmed the products are indeed modified precursor with a
phosphate group at the last serine, as it appeared to be in the lasso peptide. We once again
used peadenin lasso peptide as a substrate and repeated the assay with new ThcoK kinase and
again we did not observe any activity129 (Figure 4.23).
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Figure4.23: Phosphorylation assay using ThcoK and (a) paeninodin or (b) GP-PadeA.
In conclusion, we clearly showed by the in vitro studies that the kinase could only modify the
precursor peptide of the lasso peptide. The kinase phosphorylated the C-terminal Ser of the
precursor peptide selectively prior to processing by the B1, B2 and C homologues, thus yielding
a phosphorylated lasso peptide (Figure 4.24).
Figure4.24:Proposed schematic of paeninodin biosynthesis. Precursor peptide PadeA is phosphorylated at its C-
terminal Ser by PadeK, and is then processed into the mature, phosphorylated lasso peptide by PadeB1, PadeB2
and PadeC. Cellular export of the lasso peptide is accomplished by ABC transporter PadeD.
4.6 Biochemical Characterization of PadeK and ThcoK Kinase.
4.6.1 Bioinformatic analysis of the kinases
In order to characterize the PadeK and ThcoK kinases, we firstly performed a bioinformatic
analysis on them. Results showed that parts of the lasso peptide precursor kinase shows 41 %
identities with an Hpr kinase (HprK) from Lactobacillus casei and an ATP-dependent
phosphoenolpyruvate carboxykinase (PCK) from Thermus thermophilus Hb8135-138 (Figure 4.25).
These parts are likely to be the active center of the kinase. Past research has showed that PCK
and HprK have similar ATP-binding domains and active sites. PCK and HprK generally have
similar and conserved catalytic residues of HKDD at the active center. It was shown that
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H140K161D178D179 are the key residues in the catalytic process of the crystal structure
complex of Hpr kinase (HprK) from L. casei with its substrate HPr. Asp-179 is the catalytic base
supported by His-140 to deprotonate the Ser-46 hydroxyl group, which is a prerequisite for its
phosphorylation. Lys-161 is likely to play a part in the catalysis by neutralizing the negative
charge that develops on the phosphate group during the transfer reaction and lowering the
energy of the transition state, and Asp-178 is likely to play a role in forming the metal-binding
site. All these residues of the HprK active site have their equivalent in PCK and play a similar
role in the catalytic process135-138.
Figure4.25:Comparison of ThcoK with kinases of known structures. (A) Alignment of the active site of ThcoK with
other kinases found in the PDB. (B) Hexameric and (C) monomeric structures of the HPr kinase/phosphorylase from
Lactobacillus casei (PDB: 2QMH). (D) Reaction catalyzed by the HPr kinase/phosphorylase of L. casei. (E) Dimeric
and (F) monomeric structures of the phosphoenolpyruvate carboxykinase from Thermus thermophilus Hb8 (PDB:
2PC9). (G) The reaction catalyzed by the phosphoenolpyruvate carboxykinase of T.thermophilus Hb8.
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We then used MEME to generate conserved domain motifs for all the kinases identified. All the
kinases shared two main motifs. In addition, a third motif was identified in the kinases from
Firmicutes but not Proteobacteria (Figure 4.26).
Figure4.26:Common motifs in the kinases found in lasso peptide biosynthetic gene clusters identified by comparing
25 kinase sequences from Firmicutes and 10 kinase sequences from Proteobacterial clusters using the MEME
algorithm. The locations of the different motifs in each enzyme are shown to approximate scale.
As expected, the first big motifs containing the conserved catalytic residues of the HKDD are
highly conserved in all lasso peptide precursor kinases (Figure 4.27), indicating it has a similar
catalytic mechanism with HprK and PCK129.
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Figure4.27:Multiple sequence alignment of the catalytic active site proposed in the first conserved motif of kinases
from lasso peptide biosynthetic gene clusters. The essential His-Lys-Asp-Asp motif is highlighted by red boxes.
4.6.2 Kinetic Parameters for ThcoK
After the bioinformatic analysis, we turned to study the kinetic properties of the kinase. Since
PadeK kinase is insoluble and hard to handle, we only investigated the Thcok kinase. We used
the GP-PadeA as the substrate and performed the measurement in a standard reaction assay
with a different substrate concentration. HPLC-MS was used for quantitative determination of
the modified and unmodified precursor peptide. Firstly, a time course analysis of the
phosphorylation of GP-PadeA was conducted. After incubation for 4 h with ThcoK, formation of
the final modified precursor had almost come to a maximum value. The highest conversion ratio
is about 74 %. We carried out standard assays to further calculate Kcat and Km associated with
precursor phosphorylation while varying the concentration of GP-PadeA at a constant
concentration of ThcoK at 37 °C for 20 min. For the phosphorylation of GP-PadeA, an apparent
Km of 279.3 ± 19.7 μM and a Kcat of 0.41 ± 0.02 min-1 were determined129 (Figure 4.28).
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Figure4.28:Exemplary time dependency ThcoK-catalyzed phosphorylation of GP-PadeA under assay conditions. (i)
Michaelis-Menten plot used to determine the Km and kcat values.
4.6.3 Catalytic mechanism of the Kinase
We hypothesized by bioinformatic analysis that His-Lys-Asp-Asp is the essential catalytic motif
for both kinases. To confirm this hypothesis, in vivo studies were performed by SLIM
mutagenesis. We chose these four key residues in both PadeK and ThcoK and carried out
alanine scans (Figure4.29). Expression cultures were grown under normal conditions and their
extracts were analyzed by high-resolution LC-FT-MS. No phosphorylated lasso peptide was
observed for any variant, although the overall yields of lasso peptide remained unaffected. This
proved that the lasso peptide precursor kinase has a similar mechanism and each of the four
residues is crucial to catalysis129 (Figure 4.29).
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Figure4.29: Mutational analysis study of the catalytic essential residues in the kinases (a) PadeK and (b) ThcoK. (c)
Proposed mechanism for the phosphorylation of the C-terminal Ser of a precursor peptide by PadeK.
4.6.4 Substrate specificity of ThcoK
Most natural products produced by posttranslationally modified peptides (RiPPs) are
synthesized initially as a long precursor peptide. These precursors typically contain N-terminal
leader peptides and C-terminal core peptides40. The leader peptide which is appended to the N-
terminus of the core peptide is usually important for recognition by many of the posttranslational
modification enzymes. Since the kinase here firstly modified the precursor peptide, we initially
wanted to investigate whether this modification is a leader peptide dependent or not. A
leaderless peptide (PadeA(2-23)) and a shorter truncation peptide (PadeA (13-23)) were
generated b SLIM mutagenesis. Both peptides were treated with ThcoK kinase and, surprisingly,
both could be effectively phosphorylated129. This indicates that neither the leader peptide nor
the first half of the core peptide is essential for the modification. With this information, we
RESULTS
91
generated several PadeA variants and synthesized several derivatives of the truncation peptide
of PadeA to investigate the substrate specificity of this unusual kinase further.
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Figure4.30:HPLC analysis and observed masses after in vitro assays. ThcoK was assayed with the substrates (A)
PadeA(2-23), (B) PadeA(13-23), (C) PadeA(15-23), (B) PadeA(17-23) and (E) PadeA(19-23).
Obviously, with shorter length peptides, the conversion rate decreases gradually (Figure 4.30).
This indicates that all parts of the precursor peptide contribute to the activity in such a way that
the binding affinity between ligand and the kinase is affected.
We then generated additional variants of full-length GP-PadeA, wherein the three residues
before Ser23 or the seven residues before the HYDS sequence were exchanged with the same
number of alanines. As shown in Figure 4.31, even though long stretches of the amino acid
sequence were altered in these variants, the corresponding decreases in phosphorylation
efficiency were rather small129.
Figure4.31:HPLC analysis and observed masses after in vitro assays. ThcoK was assayed with the substrates (A)
GP-PadeA 7xA-HYDS and (B) GP-PadeA 3xA-S.
We have already shown that mature lasso peptide was not able to be modified by ThcoK.
However, we were curious whether the branched-cyclic peptide, whose C-terminus is not
shielded by the macrolactam ring, could be phosphorylated. To test this, pure paeninodin was
first heated at 65 °C for 4 h to generate a branched-cyclic peptide and then the mixture was
incubated with ThcoK under assay conditions. To our surprise, a significant amount of
phosphorylated, branched-cyclic peptide was observed (Figure 4.32). Because the lasso fold
itself appears to hinder access of the kinase to the C-terminal Ser, the only feasible route to
production of phosphorylated paeninodin involves modification of the precursor peptide prior to
processing129.
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Figure4.32: HPLC analysis of an in vitro assay with ThcoK and a paeninodin sample after incubation at 65 °C for 4 h.
A measurement of a sample of thermally treated paeninodin is shown as reference.
We then tried to investigate the C-terminal to study the substrate specificity of the kinase. As
shown in Figure 4.33, no modification was observed for a S23A substitution in GP-PadeA,
emphasizing the absolutely essential role of the C-terminal Ser for enzyme activity. The
PadeA(13-23) peptide consisting of the last 11 residues of the precursor peptide can be quickly
and easily accessed by chemical synthesis. We, therefore, selected it as a scaffold for more
intricate exchanges of the C-terminal Ser. As for the full-length precursor peptide, S23A
exchange abolishes enzymatic modification completely (4.33). This is also true of S23T and
S23Y substitutions, both of which preserve the side chain hydroxyl moiety. To further assess
the position of phosphate transfer, we analyzed 11-residue peptides that were methylated at the
C-terminal carboxylic acid or the Ser23 side chain. Surprisingly, phosphorylation was observed
in only trace amounts or not at all, respectively129.
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Figure4.33:HPLC analysis of in vitro assays. ThcoK was assayed with the substrates (A) GP-PadeA-S23A, (B)
PadeA(13-23)-S23A, (C) PadeA(13-23)-S23Y, (D) PadeA(13-23)-S23T, (E) PadeA(13-23)-COO-CH3 and (F)
PadeA(13-23)-S23-OCH3.
Finally, we tested a series of Ser shift variants in which the C-terminal Ser was exchanged with
Alaand a new Ser residue was introduced at position 14, 17, 20 or 22. None of these variants
were phosphorylated, confirming the importance of the C-terminal Ser for kinase activity129
(Figure 4.34).
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Figure4.34:HPLC analysis of in vitro assays. ThcoK was assayed with the substrates (A) GP-PadeA-D14S-S23A, (B)
PadeA(13-23)-E17S-S23A, (C) PadeA(13-23)- H20S-S23A (D) PadeA(13-23)-D22S-S23A.
Collectively, these results suggest that the kinase specifically recognized the serine at the C-
terminus and showed surprising enzyme promiscuous activity towards a wide scope of
substrates. Table 4.4 summarizes all the substrates we used and the relative activity129.
Table 4.4 Results of the substrate specificity assays with ThcoK.
Substrate Sequence
Conversion
Ratio
Paeninodin (lasso fold) AGPGTSTPDAFQPDPDEDVHYDS 0
GP-PadeA GPMKKQYSKPSLEVLDVHQTMAGPGTSTPDAFQPD
PDEDVHYDS
74.4±4.3
PadeA(2-23) GPGTSTPDAFQPDPDEDVHYDS 50.4±2.7
PadeA(13-23) PDPDEDVHYDS 25.5±10.0
PadeA(15-23) PDEDVHYDS 18.1±3.6
PadeA(17-23) EDVHYDS 8.2±2.0
PadeA(19-23) VHYDS 3.4±0.2
GP-PadeA 7xA-HYDS GPMKKQYSKPSLEVLDVHQTMAGPGTSTPDAFQAA
AAAAAHYDS
41.2±7.8
GP-PadeA 3xA-S GPMKKQYSKPSLEVLDVHQTMAGPGTSTPDAFQPD
PDEDVAAAS
39.7±2.1
GP-PadeA S23A GPMKKQYSKPSLEVLDVHQTMAGPGTSTPDAFQPD
PDEDVHYDA
0
Unthreaded paeninodin AGPGTSTPDAFQPDPDEDVHYDS 54.4±9.9
PadeA(13-23)-S23A PDPDEDVHYDA 0
PadeA(13-23)-S23Y PDPDEDVHYDY 0
PadeA(13-23)-S23T PDPDEDVHYDT 0
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PadeA(13-23)-COO-CH3 PDPDEDVHYDS-COO-CH3 ＜1
PadeA(13-23)-S23-OCH3 PDPDEDVHYD(S-OCH3) 0
PadeA(13-23)-D14S-
S23A
PSPDEDVHYDA 0
PadeA(13-23)-E17S-
S23A
PDPDSDVHYDA 0
PadeA(13-23)-H20S-
S23A
PDPDEDVSYDA 0
PadeA(13-23)-D22S-
S23A
PDPDEDVHYSA 0
4.6.5 Phosphorylation occurs at the C-terminal Ser23 side chain
The kinase specifically recognized the serine at the C-terminus, but we cannot judge the
modification position based on an in vitro assay. Three assays were employed to prove the
modification position to definitively prove the site of phosphorylation: MS2 analysis, NMR
analysis and a chemical modification assay.
4.6.5.1 MS2 analysis of the in vitro assays
Firstly, when we used PadeA(13-23) as the substrate in the in vitro assays, the MS2
fragmentation demonstrated clearly that the phosphate group was attached at the C-terminal
serine (Figure 4.35).
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Figure4.35. High-resolution LC-FT-MS analysis and extracted ion chromatograms of the in vitro assay with ThcoK
and PadeA(13-23) as substrate. (A) Extracted ion chromatograms and LC-MS analysis of the in vitro assays. (B) MS2
fragmentation of substrate and modified peptide.
When we used PadeA(13-23)-COO-CH3 as the substrate, trace amounts of the predicted
modified peptides were detected. Compared with the spectrum obtained from PadeA(13-23)
(Figure 4.36), the MS2 fragmentation of both modified peptide and unmodified peptide gives a
clearly y and b series of fragment ions. The b series fragment observed plus a phosphate group
at the modification peptide demonstrates that the phosphate group is attached at the side chain.
RESULTS
98
Figure4.36.High-resolution LC-FT-MS analysis and extracted ion chromatograms of the in vitro assay with ThcoK
and PadeA(13-23)-S23-OCH3 as a substrate. (A) Extracted ion chromatograms and LC-MS analysis of the in vitro
assays. (B) MS2 fragmentation of substrate and modified peptide.
4.6.5.2 Esterification assays
Secondly, we wanted to find a chemical modification method132. Thus, an optimized modification
assay was performed on a large scale on PadeA(13-23) to obtain pure, phosphorylated peptide.
Additionally, a version of the 11-residue peptide already carrying a phosphorylated Ser side
chain (PadeA(13-23)-Ser23-OPO32-) was chemically synthesized as a reference.
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We, firstly, tried esterification assays using these peptides.53 Each 10 μg peptide was
redissolved in 100 μl 2M methanolic HCl and esterification was allowed to proceed at 25 °C for
4 h. Solvent was then removed by lyophilization and the resulting sample was redissolved in
100 μl of 20 % acetonitrile. LC-MS analysis clearly suggested that the entire carboxyl group in
the peptides was esterified. All the peptides were converted into new peptides with six esters,
indicating that five carboxyl groups at the side chain and one carboxyl group at the C-terminus
were esterified (Figure 4.37). On the other hand, the peptides we synthesized by in vitro assays
and the one we synthesized from Biomatik have the same behavior in the assays. In both cases,
we could find the peptide with six esters plus one phosphate. Phosphate methyl esters were not
observed under these conditions. Further MS2 fragmentation demonstrated clearly that the
phosphate group was attached at the side chain of the last Serine at the C-terminus of our
peptide synthesized in vitro129 (Figure 4.38).
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Figure4.37:Results of the esterification assays of (a) the enzymatically modified 11-residue peptide and (b) the
isolated phosphorylated paenonodin lasso peptide. Excerpts of the 1H-31P HMBC spectra of (c) enzymatically
produced and (d) synthetically derived PadeA(13-23)-Ser23-OPO32- that show the phosphoryl 31P–Ser23 b-H cross
peaks.
After we calculated the modification position from the in vitro assays, we repeated the
esterification assays with paeninodin lasso peptide and phosphorylated paeninodin lasso
peptide. Both modified peadenin and unmodified peadenin were converted into peptides with six
esters, indicating the phosphate group is also attached at the side chain of the Serine at the C-
terminus129 (Figure 4.37).
Further MS2 fragmentation experiments also demonstrated our hypothesis clearly (Figure 4.39).
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Figure4.38:HPLC analysis of the esterification assays with enzymatically generated PadeA(13-23)-Ser23-OPO32- (A)
HPLC chromatogram of a PadeA(13-23)-Ser23-OPO32- reference. (B) HPLC chromatogram of PadeA(13-23)-Ser23-
OPO32- after the esterification assay. (C) High-resolution MS signals observed before and after the assay reaction.
MS2 fragmentation spectra of (D) PadeA(13-23)-Ser23-OPO32- and (E) fully esterified PadeA(13-23)-Ser23-OPO32-
.The same results were obtained when using chemically synthesized PadeA(13-23)-Ser23-OPO32- instead of the
enzymatically generated one. The same masses minus the phosphate group were observed for the esterification
assay with unphosphorylated PadeA(13-23), showing that it was also methylated at six different positions.
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Figure4.39:HPLC analysis of the esterification assays with paeninodin-OPO32-. (A) HPLC chromatogram of a
paeninodin-OPO32- reference. (B) HPLC chromatogram of paeninodin-OPO32- after the esterification reaction. (C)
High-resolution MS signals observed before and after the assay reaction. MS2 fragmentation spectra of (D) the
paeninodin-OPO32- reference and (E) fully esterified paeninodin-OPO32-. The same number of six methylations was
observed in the esterification assay with unmodified paeninodin.
4.6.5.3 NMR analysis
NMR studies were performed with the synthetically and enzymatically phosphorylated 11-
residue peptides as an additional control.
Nearly identical NMR spectra were obtained for both peptides and, after signal assignment, a
long-range correlation between the -hydrogen of Ser23 and phosphor could be observed in
1H-31P HMBC spectra (Figures 4.40and 4.41). Hence, it could be determined unambiguously
RESULTS
103
that ThcoK exclusively transfers a phosphate group from ATP to the side chain of the C-terminal
Ser, as proposed earlier129.
Figure4.40:1H-31P HMBC spectrum of enzymatically produced PadeA(13-23)-Ser-OPO32- in H2O/D2O (9:1). The
spectrum was recorded on a Bruker Avance III 500 Mhz spectrometer at 298 K.
Figure4.41:1H-31P HMBC spectrum of chemically synthesized PadeA(13-23)-Ser-OPO32- in H2O/D2O (9:1). The
spectrum was recorded on a Bruker Avance III 500 Mhz spectrometer at 298 K.
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In conclusion, we clearly demonstrated by using three different methods that the kinase in the
lasso peptide gene cluster could modify the side chain of the serine at the C-
terminusspecifically. This is a rare example of a kinase that modified the C-terminus of a long
peptide.
4.7 Bioinformatic Analysis of Putative Lasso Peptide Biosynthetic
Gene Clusters Featuring Kinase-Encoding Genes
The majority of all known lasso peptides originate from either Proteobacterial or Actinobacterial
sources97. Paeninodin is the first lasso peptide isolated from Firmicutes and the first
phosphorylated lasso peptide reported so far. This example proved that there are a group of
novel and cryptic lasso peptide gene clusters which have been overlooked in the past. The
discovery of this first lasso peptide tailoring enzyme opens up a new lasso peptide biosynthesis
world.
We then performed a phylogenetic analysis of C protein and its homologies. Phylogenetic trees
derived from the C gene homologues have an interesting branching (Figure 4.42). These trees
could segregate into five clades, which is in general accordance with the differences of their
biosynthetic gene cluster. Hence, there is one group of Actinobacterial clusters, one of Firmicute
clusters and three of Proteobacterial clusters. The latter is divided into clusters with a simple
ABC organization adjacent to a gene encoding a lasso peptide isopeptidase, clusters containing
an additional gene encoding an ABC transporter (D protein) and clusters featuring genes coding
for both a D protein and a putative kinase129.
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Figure4.42:Phylogenetic tree of the C proteins of different lasso peptide biosynthetic gene clusters. The red asterisks
mark the clusters containing kinase.
It is highly likely that the lasso peptides have similar functions with similar organization of the
biosynthetic machinery, thus, it would be smarter to classify the lasso peptides by the
organization of their biosynthetic gene cluster. Therefore, we hypothesize that most lasso
peptides could be generally divided into five clades. It appears that the five lasso peptide clades
evolved by divergence from a common ancestor. This is reasonable when considering the
known and presumed biological functions of these peptides. The clusters containing
isopeptidase from Proteobacteria, which lack an ABC transporter, are able to catabolize their
lasso peptides, indicating that the peptides play a role in signaling or function in scavenging
through a catch-and-release mechanism. On the other hand, lasso peptide gene clusters from
Actinobacteria and Proteobacteria, which feature an ABC transporter, often produce lasso
peptides with antibacterial properties, indicating that the molecules are synthesized and then
exported for competition. That the organization of these gene clusters is different, indicates that
they arose independently. The newly identified clusters from Firmicutes featuring kinase and the
potential clusters featuring kinase from Proteobacteria represent two new families of lasso
peptide gene clusters. Although both clusters contain a kinase, there is little similarity between
their precursor peptides other than the C-terminal serine. Thus, it seems that Firmicutes and
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Proteobacteria evolved a similar strategy independently to produce phosphorylated lasso
peptides. The diversity of the biosynthetic machinery and functions of the molecules make them
an intriguing class of bacterial natural products.
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5. Discussion
In this study, we describe the first example of modified lasso peptide and the first tailoring
enzyme involved in the lasso peptide biosynthesis pathway. The biosynthetic pathway of
modified lasso peptide has been delineated through in vivo and in vitro studies. This unusual
kinase recognized the last serine of the precursor peptide specifically and transferred a
phosphate group onto the C-terminus of the peptide, resulting in a modified precursor peptide,
and then folded into a modified lasso peptide. This first lasso peptide isolated from Firmicutes
revealed several cryptic, novel lasso peptide gene clusters overlooked in the past. The kinase
studied here and several potential transferases open up new avenues for engineering and
diversifying the chemical nature of lasso peptides.
5.1 Isolation and Characterization of the Paeninodin and
Phosphorylated Paeninodin Lasso Peptide
5.1.1 Paenibacillusas a new source for novel natural products
Paenibacillus is a genus originally included within the genus Bacillus and then reclassified as
paenibacillus. As the name implies,paene in Latin means almost, so bacteria belonging to this
genus are almost Bacilli. Similar to Bacillus, this genus has been detected in all kinds of
environments. It has been shown to be important for agriculture and horticulture. Exemplary are
P. larvae, which is known to cause American foulbrood in honeybees139, pattern-forming strains,
such as P. dendritiformis studied in this thesis, which are already known to develop complex
colonies with complex architectures140, and P. polymyxa, which is capable of fixing nitrogen and
is used, therefore, in agriculture and horticulture141.
This genus has been shown as a new source for novel natural products. P. larvae, for example,
a pathogen that causes American foulbrood, which is the most serious infectious disease of
honey bees, has been shown to produce diverse natural products142. These secondary
metabolites, such as nonribosomal peptides and peptide–polyketide hybrids, are highly likely to
be involved in virulence and pathogenicity towards the bee larvae. These natural products
included Sevadicin-A nonribosomal tripeptide, bacillibactin-siderophores, paenilarvins-iturin-like
lipopeptides and paenilamicins-complex peptide-polyketide hybrids (Figure 5.1).
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Figure5.1:Known compounds isolated from P. larvae(Figure from ref 142).
Genomes sequence projects in recent years have revealed the presence of an impressive
number of secondary metabolite clusters. There are more cryptic gene clusters in P. larvae,
besides the four gene clusters responsible for the biosynthesis of known compounds isolated, of
which the natural products are not yet known.
Beside the P. larvae, another 56 Paenibacillus strains have been sequenced and all of them
contain diverse secondary metabolite gene clusters. These Paenibacillus seem to represent a
new and rich source of secondary metabolites that need to be explored in the future.
P. dendritiformis is a species of pattern-forming bacteria, first discovered in the early 1990s by
Ben-Jacob's group. It is a social microorganism that forms colonies with complex and dynamic
architectures143. The complete genome sequence of this strain was sequenced in 2012. The
latter provides an excellent opportunity that facilitates the exploitation of natural product
discovery in this strain. No secondary metabolites have been isolated from P. dendritiformis so
far, but a lethal protein was produced in response to competition between sibling colonies143.
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Genome analysis of the P. dendritiformis chromosome by antismash identified 12 secondary
metabolite gene clusters, suggesting the possibility of an extensive secondary metabolism
(Table 5.1). Most of them encode for peptides of nonribosomal origin, though PKS and hybrid
PKS-NRPS systems are present as well. Moreover, RiPPs gene clusters have also been
detected.
Table5.1. Potential natural products in biosynthetic gene clusters from P. dendritiformis.
No. Cluster location Predicted products
1 WP_006674824.1-WP_006674859.1 Nrps-t1pks
2 WP_006675255.1-WP_006675330.1 Nrps-transatpks-t1pks
3 WP_040730674.1-WP_006676104.1 Bacteriocin
4 WP_006677185.1- WP_006677207.1 Bacteriocin-nrps
5 WP_006678389.1- WP_006678408.1 Lassopeptide
6 WP_050979467.1-WP_006678468.1 NRPS
7 WP_006679151.1-WP_006679160.1 Nrps-arylpolyene
8 WP_006679448.1- WP_006679450.1 NRPS
9 WP_006679469.1-WP_006679497.1 NRPS
10 WP_006679486.1- WP_006679504.1 NRPS
11 EHQ59413.1 NRPS
12 WP_006679973.1- WP_006679985.1 Ectoine
Notably, the gene cluster No. 5 is the paeninodin lasso peptide gene cluster studied in this
thesis. The C and D proteins were identified in the prediction by antismash.
5.1.2 Discovery and isolation of the paeninodin and phosphorylated paeninodin
lasso peptide
The isolation and characterization of the paeninodin and phosphorylated paeninodin lasso
peptide are reported in this work. The paeninodin lasso peptide is also known to be the first
secondary metabolite isolated from the producing strain P. dendritiformis. Moreover, modified
paeninodin is the first phosphorylated lasso peptide isolated so far. The fermentation extracts of
P. dendritiformis C454 failed to yield any lasso peptide, which proved that these lasso peptide
gene clusters are silent in lab conditions. Thus, a heterologous expression approach was
applied in this study.
Natural products gene clusters from Gram-negative species can generally typically be
expressed in greater yield using E. coli as a heterologous host. A strong promoter combined
with optimum fermentation conditions can normally trigger the production of the target
compound. However, expression of natural products gene clusters from Gram-positive species
in E. coli could be a challenging task. However, the advantage of using E. coli as a
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heterologous host is that it is well understood and easy to handle. Paeninodin lasso peptides
were produced by IPTG induction by heterologous expression in E. coli that was further purified
by HPLC. This proved that E. coli could also be a general expression host for Gram-positive
species.
The peadenin isolated contains 23 amino acids, which is the largest lasso peptide isolated so
far97. Tandem MS confirmed its primary structure, which features a nine-residue macrolactam
ring between Ala1 and Asp9. This lasso peptide bears an N-terminal Ala residue, a feature only
recently observed for a series of lasso peptides from Caulobacter sp. K31116. This could also
explain why these lasso gene clusters were overlooked in Link’s paper on “Precursor-centric
genome-mining approach for lasso peptide discovery”117. They only considered that lasso
peptides start with a glycine or cysteine. Actually, much to our surprise, all the lasso peptides
from Firmicutes prefer an N-terminal Alanine, indicating that these gene clusters are different
from all lasso peptide gene clusters reported.
Even though paeninodin is the first isolated lasso peptide from Firmicutes, we are more
interested in the function of the kinase involved in the biosynthetic pathway. Lasso peptide
modification in the literature is notably rare. There are only two examples. One is the C-terminal
methylation of lassomycin, which has a methyltransferase involved in the lasso peptide gene
cluster104. The other is the Trp hydroxylation of some RES-701 family lasso peptides whose
biosynthetic pathway has not yet been identified.
The kinases identified in lasso peptide biosynthetic gene clusters from Firmicutes are often
annotated as homologues of HPr kinase (e.g. from Lactococcuscasei). Hpr kinase is the key
protein in the regulation of carbon metabolism in Bacillus subtilis and many other Gram-positive
bacteria136, 137. At the beginning, we hypothesized that this kinase may play a role in regulation
of paeninodin lasso peptide production. However, a small peak with similar retention time to that
of paeninodin in the high-resolution LC-FT-MS analysis of cell extracts caught our attention.
Closer inspection showed that it belonged to a compound with the molecular weight of the lasso
peptide plus a phosphate group. Based on MS2 results, we proposed that the compound results
from phosphorylation of the C-terminal Ser of paeninodin by the kinase encoded within the
cluster. Deletion of the kinase gene from the expression plasmid yielded an extract lacking the
modified compound, while non-phosphorylated paeninodin was still produced at the same level
as before. Co-expression of the knock-out plasmid with a pACYC vector carrying padeK
restored production of the phosphorylated compound. Hence, a link between the expression of
the putative kinase PadeK and the occurrence of the modified lasso peptide was established
and led us to identify a novel lasso peptide tailoring enzyme for the first time.
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5.1.3 Characterization of the paeninodin and phosphorylated paeninodin lasso
peptide
Both the paeninodin and phosphorylated paeninodin lasso peptide could be purified by two-step
preparative HPLC. Notably, the production of both compounds ispretty low compared with other
lasso peptides isolated from Proteobacteria112, 129. (The pure paeninodin lasso peptide was
obtained with a yield of ~ 0.1 mg/L; phosphorylated lasso peptide was obtained with a yield of ~
0.05 mg/L.) Considering the low production of paeninodin lasso peptide, E. coli might not be the
most ideal host for expression of these lasso peptide gene clusters from Firmicutes. A Gram-
positive related host might be a better choice. However, in our case, large-scale fermentation is
already enough for isolation of an adequate amount, so we continued to use E. coli as the first
choice.
We then characterized the paeninodin lasso peptide using the pure samples. We first tried to
substantiate that paeninodin exhibits the lasso topology predicted. A assay established
previously in which pure lasso peptide is heat-denatured and then digested with
carboxypeptidase Y was performed. The results showed that the isolated compound is only
resistant to carboxypeptidase Y prior to thermal treatment, indicating that the peptide has
adopted a lasso topology (the threaded topology of the lasso peptide occludes access of
carboxypeptidase Y to the C-terminal tail; however, following thermally-induced unthreading, the
C-terminus becomes accessible to carboxypeptidase Y)129.
We then used a previously established IM-MS method to further prove the topology of
paeninodin. The results corroborate the proposed lasso fold of the isolated compound and,
additionally, indicate that paeninodin can adopt multiple, distinct and interchangeable
conformations in its native state. We noticed that the paeninodin lasso peptide
(AGPGTSTPDAFQPDPDEDVHYDS) contains a lot of proline, aspartic acid and glutamic acid in
the potential loop region of the lasso peptide. These residues might contribute to the multiple
conformations of the lasso peptide.
Mutagenesis studies were performed to study the biosynthesis of paeninodin and propose the
plug residues of the lasso peptide. Sequence analysis of the C-terminal region of paeninodin
suggests that His20 and Tyr21 are the most suitable plug residues. Moreover, it could be shown
that the paeninodin biosynthetic machinery operates according to the same set of principles
identified for Proteobacterial systems129.
Efforts were then taken to determine the three-dimensional structure of paeninodin. As
paeninodin can adopt multiple, distinct and interchangeable conformations in its native state,
both the sparse-matrix crystal screening and NMR methods failed. Although structure
elucidation was not possible, a series of analytical assays shows that paeninodin exhibits the
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typical characteristics of a lasso peptide, in accordance with numerous previous publications.
These experimental data provide a solid body of evidence for the true lasso nature of
paeninodin. However, elucidation of its three-dimensional structure is necessary to prove this
beyond a doubt129.
5.2 Biochemical and Genetic Model for Phosphorylated Paeninodin
Biosynthesis
No experimentally supported biosynthetic pathway for lasso peptide modification has been
reported to date. This raised the question: how does the modification happen? Due to the
unique structure of lasso peptide, there would be two disparate biosynthetic scenarios for lasso
peptide modification (Figure 5.2). The first scenario could be that the lasso peptide is, firstly,
synthesized by the mature enzymes and then modified by the tailoring enzymes to yield the final
products. A second scenario could be that the kinase, sulfotransferase and other potential
tailing enzymes encoded by the lasso peptide gene cluster, firstly, modify the precursor to form
modified precursor, then the mature enzymes transfer the modified precursor into the final lasso
peptide.
5.2.1 A biosynthetic pathway for phosphorylated paeninodin assembly
We heterologously expressed and isolated the PadeK kinase and performed in vitro studies to
investigate how paeninodin becomes phosphorylated. Two potential substrates (the padeA
precursor peptide and paeninodin) were also prepared. In vitro sudies clearly demonstrated that
the PadeK kinase could only modify the precursor peptide. Thus, the biosynthetic pathway of
modified lasso peptide was delineated. It turned out that the second scenario is right, which is
that the kinase acts on the precursor peptide prior to processing by the lasso peptide
biosynthetic enzymes.
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Figure5.2:Two potential biosynthetic pathway for modified lasso peptide.
We searched our genome mining results for a suitable homologue due to difficulties isolating
PadeKas as well as its weak activity. We identified a kinase from the cluster of T. composti
KWC4 (ThcoK) that could be readily isolated in high yields and be used to facilitate homologous
exchange. When pure ThcoK was subjected to in vitro assays with the lasso peptide and
unmodified precursor peptideGP-PadeA, phosphorylation of the precursor peptide (~ 80 %
conversion), but not the lasso peptide was observed.
We replaced PadeK with ThcoK in our heterologous expression system and the
phosphorylated lasso peptide was found to be the main product in the presence of ThcoK.
These in vivo and in vitro experiments for both PadeK and ThcoK kinase clearly provided us a
rare glimpse of how lasso peptide further increases its chemical diversity and provide a way for
the generation of novel lasso peptide analogs129.
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5.2.2 Putative regulation of the phosphorylated paeninodin biosynthesis
A natural products biosynthetic gene cluster normally contains regulatory genes. This is also
true for this newly identified paeninodin lasso peptide gene cluster. A putative transcriptional
regulator was identified at the downstream of the whole paeninodin lasso gene cluster (Figure
5.3).
Figure5.3:Putative regulator involved in paeninodin biosynthesis.
This transcriptional regulator contains a XER-family (xenobiotic response element) HTH(Helix-
turn-helix) domain144 (Figure 5.4). This kind of regulator is believed to be involved in several late
growth processes. We hypothesized that this regulator takes part in the biosynthesis of
paeninodin in the native strain and could be a reason why no lasso peptide was detected in lab
conditions.
Figure5.4:Conserved domain of the potential regulator.
5.2.3 Putative function of the phosphorylated paeninodin
The natural function of phosphorylated paeninodin is still elusive. Past research has showed
that lasso peptide can generally be divided into two clades based on whether the pathway
features an ABC-transporter or an isopeptidase. The gene clusters for recently newly
discovered astexins, caulosegnins and xanthomonin have a TonB transporter and an
isopeptidase to specifically deconstruct the lasso peptide in the cell113. The natural function of
this class of lasso peptides is believed to be a type of scavenging molecule that is involved in
species competition. On the other hand, the gene cluster for MccJ25, capistruin and lariatin has
an ABC transporter serving as an exporter and immunity factor of the lasso peptides97. All these
molecules are antimicrobial peptides. An ABC transporter could alwaysbe observed in the gene
cluster for peadenin lasso peptide and its homologues. However, notably, the PadeD shows
very low identities (30 %) to MccjD. Considering these gene clusters featured unusual tailoring
enzymes, they are distinct from both clades mentioned above. The lasso peptide from these
gene clusters is highly likely to function as an antimicrobial peptide, since the ABC transporter is
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present. The phosphate group attached at the C-terminus of the lasso peptide could provide a
means of diversifying the lasso peptide surfaces. In particular, the phosphate group with its
large hydrated shell could increase the negative charge of lasso peptide significantly, thus,
increasing its binding affinity to the target receptor. On the other hand, nature widely
choosesthe phosphate group to modify protein. The phosphate group has special properties
that can be exploited to regulate critical biological functions when attached to proteins. The
phosphate group generally serves as a switch to promote inducible protein-protein interactions,
which allows signal transduction networks to transmit transient signals in response to
extracellular stimuli. Thus, a second guess for the function of the phosphorylated peadenin
would be that it serves as a signal molecule that corresponds to the environmental
transformation. It could also be possible that this modification is a self-protective mechanism.
The phosphate group could be removed during the transporting process. The last hypothesis is
that the phosphorylated precursor peptide is only an intermediate of other tailoring enzymes.
The uncharacterized nucleotidyltransferase, for example, might use it as a substrate and will
perform another modification at the same position. More future effort needs to be placed on the
natural function of these fascinating molecules.
5.3 Characterization of the Lasso Peptide Precursor Kinase
5.3.1 Characterization of the precursor kinases PadeK and ThcoK
After we figured out how the paeninodin lasso peptide was modified, we then turned our
attention to the characterization of the precursor kinases. After demonstrating the much higher
in vivo and in vitro phosphorylation activity of ThcoK compared with PadeK towards PadeA, full
characterization of ThcoK was performed. Kinetic parameters for the modification of GP-PadeA
were obtained by varying the substrate concentration under constant enzyme concentration. In
this way, the Michaelis-Menten parameters Km = 279 ± 19.7 M and kcat = 0.41 ± 0.02 min-1 for
ThcoK were determined129.
We also successfully identified the catalytic mechanism of these kinases by informatics analysis
combined with mutagenesis studies. Because ThcoK and other kinases identified in lasso
peptide biosynthetic gene clusters from Firmicutes are often annotated as homologues of HPr
kinase (e.g. from Lactococcus casei) and phosphoenolpyruvate carboxykinase (e.g. from
Thermus thermophilus Hb8), we then checked all the conserved regions of kinases from these
families. Intriguingly, all of these kinases appear to share conserved active site motifs consisting
of one His, one Lys and two Asp residues (HKDD). The catalytic mechanism for L. casei HPr
kinase has been studied previously. The roles of these residues in catalysis (His140-Lys161-
Asp178-Asp179) can be derived from the co-crystal structure of the kinase with its substrate.
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The conjugate base of Asp179, stabilized by His140, deprotonates the Ser46 side chain of the
HPr substrate, which then abstracts the -PO43- group of ATP through nucleophilic attack.
Lys161 and Asp178 facilitate the binding of ATP by counteracting negative charges and
coordinating a metal ion, respectively135, 137, 138.
We hypothesize that a similar mode of catalysis is feasible for PadeK, ThcoK and their
homologues. Indeed, this was confirmed by mutagenesis. We generated single or quadruple
Ala variants of these residues, as well as double Asp-to-Ala variants of both PadeK and ThcoK
in our lasso peptide production plasmids. No phosphorylated lasso peptide was observed for
any variant, although the overall yields of lasso peptide remained unaffected. This suggests
strongly that the kinase variants were rendered inactive and that each of the four residues is
crucial to catalysis129.
We then investigated the substrate specificity of ThcoK. Several questions needed to be
addressed for these studies: Firstly, the minimal length of a peptide necessary for modification,
secondly, the motifs recognized by the kinase and, thirdly, the precise site of phosphate addition.
To address these questions, a wide variety of peptides were treated with ThcoK under our
established assay conditions. These results collectively suggest that the kinase specifically
recognized the serine at the C-terminus and showed surprising enzyme-promiscuous activity
towards a wide scope of substrates129.
5.3.2 Lasso peptide precursor kinase as a useful biocatalyst
Phosphorylation is generally one of the most prominent types of posttranslational modification of
protein, because of its versatility and ready reversibility. It commonly forms a phosphate ester at
the side chain of serine, Thr and tyrosine residues, although phosphorylation of six other amino
acids is chemically possible (arginine, cysteine, lysine, histidine, glutamine and asparagine),
and in many cases is known to occur. Here, we show a rare example that this family of kinases
recognized the serine at the C-terminus specifically.
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Figure5.5:Potential application of the lasso peptide precursor kinase.
It turned out that, in spite of the strict requirement for a C-terminal Ser with free hydroxyl and
carboxyl groups, the enzyme shows a remarkable degree of promiscuity toward its substrates,
to the extent that their primary structures may otherwise be completely flexible. To the best of
our knowledge, no other kinase has been shown to phosphorylate a C-terminal Ser, whereas
those which phosphorylate an internal Ser residue are quite common in nature. This unique
combination of relaxed substrate specificity and highly selective modification of a C-terminal Ser
makes these kinases interesting candidates for applications in synthetic biology, and could
complement the chemical toolbox available for in vitro peptide synthesis and modification nicely
(Figure 5.5). Future studies could aim at evolving one of these kinases for robustness, speed
and efficiency for these purposes129.
5.4 Perspective and Outlook
Microorganisms often produce diverse secondary metabolites that are not directly involved in
the normal growth, development or reproduction of the producing organism, but take part in
important physiological and ecological roles, such as defense strategies. These secondary
metabolites have been widely used by humans as medicines, flavorings and recreational drugs1, 16.
The discovery and isolation of natural products in the past has often relied on bioassay-guided
methods. This strategy has indeed led to the discovery of many bioactive compounds used in
clinical therapy, such as artemisinin and vancomycin. In recent years, with the concurrent
advances in microbial genome sequencing projects, fundamental understanding of natural
product biosynthesis and analytical technologies, we are entering a Golden Age of natural
products drug discovery145. In many cases, a single strain has revealed a multitude of gene
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clusters associated with the biosynthesis of secondary metabolites. In combination with
bioinformatics analysis, this has paved the way for the mining of genomes for diverse unknown
bioactive compounds.
The genes generally responsible for the biosynthesis of natural products are often clustered
together in a genome. This is also true for the P. dendritiformis strain studied in this thesis. The
12 different natural products gene clusters identified put P. dendritiformis forward as a rich
source for the isolation and the structural characterization of novel natural products. However it
is notable that most of the gene clusters identified remain “cryptic” with respect to their cognate
metabolites.
Several approaches have been developed during recent years to activate the “cryptic” gene
clusters, leading to a successful characterization of new natural products146. The first method is
called “altering of chemical and physical conditions.” This includes methods such as using
Histone deacetylases (HDACs) as elicitors or with cocultivation in the presence of other species.
A second strategy is called “genetic modification approaches.” The latter includes method such
as ribosome engineering and alteration of the transcriptional machinery, manipulation of
pathway-specific and global regulators, and using quorum sensing as a tool for the regulation of
secondary metabolism. The third method is called “heterologous expression.” Series of useful,
engineered heterologous expression hosts are available for this approach, such as E. coli and
yeast.
In this thesis, the genome mining and heterologous expression strategy were successfully
applied resulting in the discovery of paeninodin and phosphorylated paeninodin. This is the first
natural product isolated from P. dendritiformis. Further investigation on other gene clusters
identified could lead to discovery of more compounds from this strain.
Paeninodin is also the first lasso peptide isolated from Firmicutes. Our genome-mining data
revealed that the lasso peptide gene clusters in Firmicutes represent a completely new family of
lasso peptide. Further investigation into the isolation and bioactivity of these novel lasso
peptides will open up new avenues for lasso peptides.
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Figure5.6:Potential tailoring enzymes involved in lasso peptide modification.
In addition, the identification of various architectures of lasso peptide clusters with potential
tailoring enzymes are a “gold mine” that will facilitate diversifying the lasso peptide structure and,
hence, improve the physiological and biochemical properties of these fascinating molecules in
the future (Figure 5.6). Moreover, these potential tailoring enzymes could also enrich chemists’
enzyme toolkits and would facilitate drug design strategies in the future.
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7. Appendix
DNA sequences of the studied proteins
In the following, the DNA sequences of the proteins recombinantly produced in this work are
shown.
PadeK
ATGACCGAACGAGCAGCGGTAAGGACTGACCATTATAAAGCTTTTGGCTTCCGTATTGAGAGCGACTTTGTATTACC
GGAACTGCCTCCGGCTGGCGAGCGCGAGCCTCTGGACAACATTACGGTACGGCGGACAGACTTGCAGCCTCTCTGGA
ACAGCTCCATTCATTTCTATGGAAACTTCGCTATTCTGGATCACGGCCGTACGGTTATGTTTCGGGTACCTGGGGCT
GCCATATATGCGGTACAGGATGCCTCCTCCATCCTGGTCTCTCCGTTCGATCAGGCGGAAGAGAACTGGGTTCGGCT
TTTTATTCTGGGGACTTGTATGGGCATTATCTTGCTGCAGCGCAAAATTATGCCTTTGCACGGCAGCGCCGTAGCTA
TTGACGGGAAGGCCTATGCCATTATCGGCGAATCCGGGGCGGGCAAATCGACCTTGGCCTTGCACCTGGTGTCCGAG
GGATATCCGCTGCTTAGCGATGATGTTATTCCCGTCGTGATGACTCAAGGCTCTCCTTGGGTTGTTCCTTCTTACCC
ACAGCAAAAATTATGGCTGGACACACTGAAGCACATGGGAATGGACAATGCCAATTACACCCCGCTTTATGAGCGGA
ATACGAAATTTGCCGTGCCCGTGGGGTCCAACTTTCATGATGAACCTCTTCCGTTGGCAAGTATCTTTGAGTTGGTT
CCATGGGATGCCGCAACTCATATTGCGCCGATCCAGGGGATGGAGCGCTTTCGCGTCCTCTTTCACCATACGTACCG
TAATTTTTTGGTGCAGCCGCTGGGATTGATGGAATGGCACTTCAAGACCCTGTCATCCTTCGTTCACCAGATCGGGA
TGTACCGTTTACACCGTCCCATGGTTGGATTCAGCACGCTTGATCTGACATCGCACATTTTAAACATTACCCGGCAA
GGAGAGAATGACCAATGA
ThocK
GTGACCAGGACAAATACCGGCTATCGGTACCGGGCCTTCGGGCTCCGGATTGACAGCGACATCCCGCTGC
CCGAACTCGGAGACGGCACCCGGCCTGACGGCGACGCCGATCTGACCGTCGTCCGCTGCGGCGAGGCGGA
GCCGGAATGGGCGGAAGGCGGAGGCGGCGGCAGACTGTATGCGGCGGAAGGCATCGTCTCGTTCCGGGTT
CCGCAGACGGCCGCTTTCCGGATCACGAACGGCAACCGGATCGAAGTGCATGCTTACAGCGGAGCAGACG
AGGACCGGATCCGCCTGTACGTGCTCGGCACGTGCATGGGCGCGCTCCTGCTGCAGCGGCGCATCCTGCC
GCTTCACGGCAGCGTCGTGGCGCGCGACGGGCGCGCATACGCCATCGTCGGCGAATCGGGCGCGGGCAAG
TCGACGATGTCCGCGGCGCTGCTGGAACGCGGATTCCGTCTGGTGACGGACGACGTCGCCGCCATCGTCT
TCGATGAGCGCGGCACGCCGCTGGTCATGCCGGCCTACCCGCAGCAGAAGCTCTGGCAGGACAGCCTCGA
CCGGCTCCAGATTGCCGGCAGCGGGCTGAGGCCGCTCTTCGAGAGGGAGACGAAATACGCGGTCCCGGCG
GACGGCGCGTTCTGGCCGGAACCGGTGCCGCTTGTACATATCTATGAGCTCGTCCATTCCGACGGGCAGA
CGCCGGAGCTTCAGCCGATTGCCAAGCTGGAGCGGTGCTATACCTTGTATCGCCACACGTTCCGGCGGTC
GCTGATCGTGCCGTCCGGGCTTTCCGCCTGGCATTTCGAGACGGCGGTGAAGCTGGCGGAGAAGACCGGC
ATGTATCGGCTGATGCGGCCGGCGAAGGTGTTCGCGGCGCGGGAATCCGCGCGTCTCATAGAGACGCATG
CCGATGGGGAGGTGAGCCGATGA
Sequences of the proteins studied
In the following, the amino acid sequences of the proteins recombinantly produced in this work
are shown.
PadeK
MTERAAVRTDHYKAFGFRIESDFVLPELPPAGEREPLDNITVRRTDLQPLWNSSIHFYGN
FAILDHGRTVMFRVPGAAIYAVQDASSILVSPFDQAEENWVRLFILGTCMGIILLQRKIM
PLHGSAVAIDGKAYAIIGESGAGKSTLALHLVSEGYPLLSDDVIPVVMTQGSPWVVPSYP
QQKLWLDTLKHMGMDNANYTPLYERNTKFAVPVGSNFHDEPLPLASIFELVPWDAATHIA
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PIQGMERFRVLFHHTYRNFLVQPLGLMEWHFKTLSSFVHQIGMYRLHRPMVGFSTLDLTS
HILNITRQGENDQ
ThcoK
VTRTNTGYRYRAFGLRIDSDIPLPELGDGTRPDGDADLTVVRCGEAEPEWAEGGGGGRLY
AAEGIVSFRVPQTAAFRITNGNRIEVHAYSGADEDRIRLYVLGTCMGALLLQRRILPLHG
SVVARDGRAYAIVGESGAGKSTMSAALLERGFRLVTDDVAAIVFDERGTPLVMPAYPQQK
LWQDSLDRLQIAGSGLRPLFERETKYAVPADGAFWPEPVPLVHIYELVHSDGQTPELQPI
AKLERCYTLYRHTFRRSLIVPSGLSAWHFETAVKLAEKTGMYRLMRPAKVFAARESARLI
ETHADGEVSR
Table 7.1.1H chemical shifts of PadeA(13-23) in H2O/D2O (9:1) at 298 K.
amino acid NH H H others
Pro13 / 4.968
Asp14 9.046 5.164 3.113
2.902
Pro15 / 4.655
Asp16 8.588 4.814 3.102
3.003
Glu17 8.318 4.515 2.173
2.141
CH2: 2.622, 2.319
Asp18 8.521 4.851 3.083
2.952
Val19 8.085 4.162 2.112 CH3: 0.985; 0.901
His20 8.614 4.852 3.368
3.263
H2: 8.758
H4: 7.399
Tyr21 8.436 4.741 3.233
3.082
H2,6: 7.292; H3,5: 6.981
Asp22 8.688 4.902 3.085
2.933
Ser23 8.191 4.584 4.107
4.037
Table 7.2 .1H chemical shifts of chemically synthesized PadeA(13-23)-Ser-OPO32- in H2O/D2O (9:1) at 298 K.*
amino acid NH H H others
Pro13 / 4.968
Asp14 9.062 5.180 3.140
2.935
Pro15 / 4.592 2.453
Asp16 8.566 4.829 3.105
3.034
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Glu17 8.322 4.528 2.169
2.134
CH2: 2.622, 2.318
Asp18 8.534 4.868 3.094
2.988
Val19 8.093 4.173 2.106 CH3: 0.985; 0.901
His20 8.621 4.873 3.382
3.275
H2: 8.756
H4: 7.406
Tyr21 8.478 4.738 3.216
3.092
H2,6: 7.291; H3,5: 6.983
Asp22 8.657 4.909 3.094
2.939
Ser23 8.424 4.760 4.439
4.315
*chemically synthesized PadeA(13-23)-Ser-OPO32-; (31P) = 0.8 ppm; long-range 1H-31P correlation (HMBC): cross
peaks between H(Ser23) at 4.439 and 4.315 ppm and R-OPO32- at 0.8 ppm were observed.
Table 7.3.1H chemical shifts of enzymatically generated PadeA(13-23)-Ser-OPO32- in H2O/D2O (9:1) at 298 K.*
amino acid NH H H others
Pro13 / 4.968
Asp14 9.051 5.166 3.119
2.915
Pro15 / 4.592 2.453
Asp16 8.575 4.819 3.098
3.015
Glu17 8.315 4.519 2.170
2.137
CH2: 2.625, 2.320
Asp18 8.529 4.857 3.080
2.964
Val19 8.091 4.168 2.104 CH3: 0.985; 0.899
His20 8.619 4.867 3.376
3.272
H2: 8.757
H4: 7.406
Tyr21 8.480 4.729 3.223
3.082
H2,6: 7.294; H3,5: 6.985
Asp22 8.659 4.900 3.083
2.935
Ser23 8.383 4.719 4.417
4.303
*enzymatically generated PadeA(13-23)-Ser-OPO32-; (31P) = 0.7 ppm; long-range 1H-31P correlation (HMBC):
cross peaks between H(Ser23) at 4.417 and 4.303 ppm and R-OPO32- at 0.7 ppm were observed.
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Figure 7.1 NOESY spectrum of enzymatically produced PadeA(13-23)-Ser-OPO32- in H2O/D2O (9:1). The
spectrumwas recorded on a Bruker Avance 600 Mhz spectrometer at 298 K.
Appendix
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Figure 7.2 TOCSY spectrum of enzymatically produced PadeA(13-23)-Ser-OPO32- in H2O/D2O (9:1). The spectrum
was recorded on a Bruker Avance 600 Mhz spectrometer at 298 K.
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